header logo image


Page 859«..1020..858859860861..870880..»

$37M in Funding to Support Cornea Cell Therapy | InvisionMag.com – InvisionMag

October 10th, 2019 9:46 am

PHILADELPHIA Vantage EyeCare LLC has announced the addition of eight providers, bringing its total to 111 practicing in 45 locations.

It has also added a new division, Phoenixville Eye Care Specialists. A 15th division with five providers is actively planning to on-board, according to a press release. The release describes Vantage as the largest ophthalmology group in the country that remains entirely physician owned.

Staying true to the premise that quality physicians can come together to achieve scale without giving up the ability to best serve our patients, is proving to be a model that we can pragmatically grow with confidence and conviction, said Dr. Richard Prince, president of Vantage.

Heres information on the new providers:

John McLaughlin, MD, served as chief resident at Krieger Eye Institute at Sinai Baltimore after earning a medical degree from George Washington University. His experience in residency with advanced cataract procedures and surgical improvement techniques for glaucoma patients will continue the commitment of Horizon Eye Care to staying at the forefront of eye care in the Southern New Jersey Seashore area. During his education McLaughlin was the chief clinical research assistant at Scheie Eye Institute of University of Pennsylvania on the oncology team.

Lindsey Petsch, OD, is a recent graduate of Pennsylvania College of Optometry at Salus University, where she earned her doctorate of optometry after having completed a bachelor of science at Widener University. Petsch adds to the team of optometrists at Horizon Eye Care with additional training in keratoconus (steep curving of the cornea). She is a longtime area resident who is eager to bring her training and experience to the patients of southern New Jersey.

Brenton Finklea, MD, is a board-certified ophthalmologist with subspecialty training in cornea, external disease and refractive surgery. Finklea attended the University of Florida, where he was a student in the honors college, graduating magna cum laude with a bachelor of science in agricultural and biological engineering with a minor in biomechanics. During this time, he also studied music performance with emphasis on jazz saxophone. He went on to attend medical school at the University of Virginia School of Medicine. Finklea was an intern at the Inova Fairfax Hospital and Georgetown University Hospitals. Residency was at the world-renowned Wills Eye Hospital, followed by a fellowship in academic global ophthalmology at Wills Eye as well. He completed his training with a fellowship in cornea, external disease and refractive Surgery at the Duke University Eye Center.

Iga Gray, MD, joins Philadelphia Eye Associates and Wills Eye Hospital after completing her ophthalmology residency and glaucoma fellowship at the prestigious Scheie Eye Institute at the University of Pennsylvania. Gray treats a wide variety of ocular disease and specializes in the medical and surgical treatment of glaucoma and cataracts. She performs cataract surgery, traditional glaucoma surgery, minimally invasive glaucoma surgeries (MIGS) as well as a variety of laser procedures for the treatment of glaucoma.

Jamine Schecter, MD, FACS, graduated Phi Beta Kappa and magna cum laude from Haverford College. She received her medical degree from the University of Pennsylvania School of Medicine, and completed her ophthalmology residency training at the Scheie Eye Institute of the University of Pennsylvania in Philadelphia. Shechter is board-certified in ophthalmology and is a fellow of the American Academy of Ophthalmology and the American College of Surgeons. She is a member of the Pennsylvania Academy of Ophthalmology and the American Society of Cataract and Refractive Surgeons, and is on the staff at Phoenixville Hospital and Physicians Care Surgical Hospital.

Susan Wilton, MD, graduated from Bucknell University in 1981 with a bachelor of arts with honors. She followed that up with a MA in clinical psychology from the University of Arizona in 1985. She graduated from medical school at The Medical College of Pennsylvania in 1989 then completed her residency in ophthalmology. She is also a member of the Pennsylvania Academy of Ophthalmology and the Pennsylvania Medical Association.

Thomas Gulibon, OD, graduated magna cum laude from Saint Vincent College and from the Pennsylvania College of Optometry. Gulibon is board-certified in optometry, holds his therapeutic license, and serves as an examiner for the National Board of Examiners in Optometry. He is a member of the American Optometric Association, the Pennsylvania Optometric Association and the Bucks/Montgomery County Optometric Society. Gulibon specializes in contact lenses. He fits difficult cases with the latest technology including lenses for children, high astigmatism, presbyopia, keratoconus and competitive sports.

Continued here:
$37M in Funding to Support Cornea Cell Therapy | InvisionMag.com - InvisionMag

Read More...

On World Sight Day 2019, start the healthy habit to exercise your eyes daily – Firstpost

October 10th, 2019 9:46 am

On World Sight Day 2019, start the healthy habit to exercise your eyes daily - Firstpost '; $("#aid_" + id + " .dynamicArticle").find('.content-wap-ros-new').html(slot_html); createAd7(slot_id,adCount); slot_id = ''; slot_id = "infinite_content_8th_slot_no" + id; slot_html = ''; $("#aid_" + id + " .dynamicArticle").find('.content-wap-ros').html(slot_html); //createAd8(slot_id,adCount); slot_id = ''; slot_id = "infinite_content_ib_slot_no" + id; slot_html = ''; $("#aid_" + id + " .dynamicArticle").find('.content-wap-ros-ib').html(slot_html); createAd11(slot_id); /*slot_id = ''; slot_id = "infinite_content_9th_slot_no" + id; slot_html = ''; $("#aid_" + id + " .dynamicArticle").find('.ROS_Across_OOP_1x1').html(slot_html); createAd9(slot_id);*/ slot_id = ''; slot_id = "infinite_content_12th_slot_no" + id; slot_html = ''; $("#aid_" + id + " .dynamicArticle").find('.ad-block-300x250').html(slot_html); createAd12(slot_id,adCount); slot_id = ''; slot_id = "infinite_content_13th_slot_no" + id; slot_html = ''; $("#aid_" + id + " .dynamicArticle").find('.between-300x250').html(slot_html); createAd13(slot_id,adCount); } else { slot_id = ''; slot_id = "infinite_content_slot_no" + id; slot_html = ''; $("#aid_" + id + " .dynamicArticle").find('.ad-block-major').html(slot_html); createAd1(slot_id,adCount); slot_id = ''; slot_id = "infinite_content_2nd_slot_no" + id; slot_html = ''; $("#aid_" + id + " .dynamicArticle").find('.ad-block-one').html(slot_html); createAd2(slot_id,adCount); slot_id = ''; slot_id = "infinite_content_3rd_slot_no" + id; slot_html = ''; $("#aid_" + id + " .dynamicArticle").find('.ad-block-two').html(slot_html); createAd3(slot_id,adCount); if(categoryName == "India" || categoryName == "Politics"){ slot_id = "infinite_content_3rd_300x250_slot_no" + id; slot_html = ''; $("#aid_" + id + " .dynamicArticle").find('.ad-block-three').html(slot_html); createAd14(slot_id,adCount); } slot_id = ''; slot_id = "infinite_content_4th_slot_no" + id; slot_html = ''; $("#aid_" + id + " .dynamicArticle").last().find('.728X90Ad').html(slot_html); createAd4(slot_id,adCount); slot_id = ''; slot_id = "infinite_content_6th_slot_no" + id; slot_html = ''; $("#aid_" + id + " .dynamicArticle").find('.ad-block-USUK').html(slot_html); createAd6(slot_id); slot_id = ''; slot_id = "infinite_content_native_alsosee_slot_no" + id; slot_html = ''; $("#aid_" + id + " .dynamicArticle").find('.also-see_'+id).html(slot_html); createAd10(slot_id); } // activateColombia(id); //load fb comments try{ FB.XFBML.parse(); }catch(ex){} }; var colombiaCount = ''; colombiaCount = 2; function activateColombia(pp) { if ($("#div-clmb-ctn-217884-" + colombiaCount).length == 0) { if (!navigator.userAgent.match(/Android/i) && !navigator.userAgent.match(/webOS/i) && !navigator.userAgent.match(/iPhone/i) && !navigator.userAgent.match(/iPod/i) && !navigator.userAgent.match(/iPad/i) && !navigator.userAgent.match(/Blackberry/i)) { $("#aid_" + pp + " .dynamicArticle").find('.colombiaWidget').html(''); } else { $("#aid_" + pp + " .dynamicArticle").find('.colombiaWidget').html(''); } colombiaCount = parseInt(parseInt(colombiaCount) + 1); } //colombia.clearData(); } // Load Ads function createAd1(slot_id,adCount) { if(adCount != 0){ googletag.cmd.push(function() { var slot = googletag.defineSlot('/1039154/FirstPost/FirstPost_' + categoryName + '/FirstPost_' + categoryName + '_Internal_Set' + (adCount+1) + '/FirstPost_' + categoryName + '_Internal_Set' + (adCount+1) + '_300x600', [300, 600], slot_id).addService(googletag.pubads()); googletag.display(slot_id); //googletag.pubads().refresh([slot]); }); } } function createAd2(slot_id,adCount) { if(adCount != 0){ googletag.cmd.push(function() { var slot = googletag.defineSlot('/1039154/FirstPost/FirstPost_' + categoryName + '/FirstPost_' + categoryName + '_Internal_Set' + (adCount+1) + '/FirstPost_' + categoryName + '_Internal_Set' + (adCount+1) + '_300x250_1', [300, 250], slot_id).addService(googletag.pubads()); googletag.display(slot_id); //googletag.pubads().refresh([slot]); }); } } function createAd3(slot_id,adCount) { if(adCount != 0){ googletag.cmd.push(function() { var slot = googletag.defineSlot('/1039154/FirstPost/FirstPost_' + categoryName + '/FirstPost_' + categoryName + '_Internal_Set' + (adCount+1) + '/FirstPost_' + categoryName + '_Internal_Set' + (adCount+1) + '_300x250_2', [300, 250], slot_id).addService(googletag.pubads()); googletag.display(slot_id); //googletag.pubads().refresh([slot]); }); } } function createAd14(slot_id,adCount) { if(adCount != 0){ googletag.cmd.push(function() { var slot = googletag.defineSlot('/1039154/FirstPost/FirstPost_' + categoryName + '/FirstPost_' + categoryName + '_Internal_Set' + (adCount+1) + '/FirstPost_' + categoryName + '_Internal_Set' + (adCount+1) + '_300x250_3', [300, 250], slot_id).addService(googletag.pubads()); googletag.display(slot_id); //googletag.pubads().refresh([slot]); }); } } function createAd4(slot_id,adCount) { if(adCount != 0){ googletag.cmd.push(function() { var slot = googletag.defineSlot('/1039154/FirstPost/FirstPost_' + categoryName + '/FirstPost_' + categoryName + '_Internal_Set' + (adCount+1) + '/FirstPost_' + categoryName + '_Internal_Set' + (adCount+1) + '_728x90', [728, 90], slot_id).addService(googletag.pubads()); googletag.display(slot_id); //googletag.pubads().refresh([slot]); }); } } function createAd6(slot_id) { googletag.cmd.push(function() { var slot = googletag.defineSlot('/1039154/FirstPost/FirstPost_Footer/FirstPost_Footer_300x250_USUK', [300, 250], slot_id).addService(googletag.pubads()); googletag.display(slot_id); //googletag.pubads().refresh([slot]); }); } function createAd7(slot_id,adCount) { if(adCount != 0){ googletag.cmd.push(function() { var slot = googletag.defineSlot('/1039154/FirstPost_Wap_New/FirstPost_Wap_New_' + categoryName + '/FirstPost_Wap_New_' + categoryName + '_Internal_Set' + (adCount+1) + '/FirstPost_Wap_New_' + categoryName + '_Internal_Set' + (adCount+1) + '_After_Section_320x50_Middle', [320,50], slot_id).addService(googletag.pubads()); googletag.display(slot_id); //googletag.pubads().refresh([slot]); }); } } function createAd8(slot_id) { googletag.cmd.push(function() { var slot = googletag.defineSlot('/1039154/FirstPost_Wap_New/FirstPost_Wap_New_ROS/FirstPost_Wap_New_ROS_AMP_300x250', [300, 250], slot_id).addService(googletag.pubads()); googletag.display(slot_id); //googletag.pubads().refresh([slot]); }); } /*function createAd9(slot_id) { googletag.cmd.push(function() { var slot = googletag.defineSlot('/1039154/FirstPost/FirstPost_Ros/Firstpost_Ros_Across_OOP_1x1', [1,1], slot_id).addService(googletag.pubads()); googletag.display(slot_id); //googletag.pubads().refresh([slot]); }); }*/ function createAd10(slot_id) { googletag.cmd.push(function() { var slot = googletag.defineSlot('/1039154/FirstPost/FirstPost_Ros/FirstPost_Internal_also_see_article_nativead_240x260', [240,260], slot_id).addService(googletag.pubads()); googletag.display(slot_id); //googletag.pubads().refresh([slot]); }); } function createAd11(slot_id) { googletag.cmd.push(function() { var slot = googletag.defineSlot('/1039154/FirstPost_Wap_New/FirstPost_Wap_New_ROS/FirstPost_Wap_New_ROS_Top_320x35', [320,35], slot_id).addService(googletag.pubads()); googletag.display(slot_id); //googletag.pubads().refresh([slot]); }); } function createAd12(slot_id,adCount) { if(adCount != 0){ googletag.cmd.push(function() { var slot = googletag.defineSlot('/1039154/FirstPost_Wap_New/FirstPost_Wap_New_' + categoryName + '/FirstPost_Wap_New_' + categoryName + '_Internal_Set' + (adCount+1) + '/FirstPost_Wap_New_' + categoryName + '_Internal_Set' + (adCount+1) + '_Between_Sections_300x250_1', [300,250], slot_id).addService(googletag.pubads()); googletag.display(slot_id); //googletag.pubads().refresh([slot]); }); } } function createAd13(slot_id,adCount) { if(adCount != 0){ googletag.cmd.push(function() { var slot = googletag.defineSlot('/1039154/FirstPost_Wap_New/FirstPost_Wap_New_' + categoryName + '/FirstPost_Wap_New_' + categoryName + '_Internal_Set' + (adCount+1) + '/FirstPost_Wap_New_' + categoryName + '_Internal_Set' + (adCount+1) + '_Between_Sections_300x250_2', [300,250], slot_id).addService(googletag.pubads()); googletag.display(slot_id); //googletag.pubads().refresh([slot]); }); } } function zealAd(postId){ console.log("zeal -> "+postId); /*Ads.init(function() { AdSDK.add('ADID_1_'+postId); AdSDK.add('ADID_2_'+postId, 'ADID_3_'+postId, 'ADID_4_'+postId, 'ADID_5_'+postId); });*/ } function compositeAds() { var D=new Date(),d=document,b='body',ce='createElement',ac='appendChild',st='style',ds='display',n='none',gi='getElementById',lp=d.location.protocol,wp=lp.indexOf('http')==0?lp:'https:'; var i=d[ce]('iframe');i[st][ds]=n;d[gi]('M367441ScriptRootC281455')[ac](i);try{var iw=i.contentWindow.document;iw.open();iw.writeln(''+'dy>'+'ml>');iw.close();var c=iw[b];} catch(e){var iw=d;var c=d[gi]('M367441ScriptRootC281455');}var dv=iw[ce]('div');dv.id='MG_ID';dv[st][ds]=n;dv.innerHTML=281455;c[ac](dv); var s=iw[ce]('script');s.async='async';s.defer='defer';s.charset='utf-8';s.src=wp+'//jsc.mgid.com/f/i/firstpost.com.281455.js?t='+D.getYear()+D.getMonth()+D.getUTCDate()+D.getUTCHours();c[ac](s); } function compositeAdsInArticle(post_id) { if($('#article-full-content_'+post_id+' > div[id ^= "M367441ScriptRootC281457"]').length == 0){ $('').insertAfter($('#article-full-content_'+post_id+'>p:eq(3)')); var D=new Date(),d=document,b='body',ce='createElement',ac='appendChild',st='style',ds='display',n='none',gi='getElementById',lp=d.location.protocol,wp=lp.indexOf('http')==0?lp:'https:'; var i=d[ce]('iframe');i[st][ds]=n;d[gi]('M367441ScriptRootC281457')[ac](i);try{var iw=i.contentWindow.document;iw.open();iw.writeln(''+'dy>'+'ml>');iw.close();var c=iw[b];} catch(e){var iw=d;var c=d[gi]('M367441ScriptRootC281457');}var dv=iw[ce]('div');dv.id='MG_ID';dv[st][ds]=n;dv.innerHTML=281457;c[ac](dv); var s=iw[ce]('script');s.async='async';s.defer='defer';s.charset='utf-8';s.src=wp+'//jsc.mgid.com/f/i/firstpost.com.281457.js?t='+D.getYear()+D.getMonth()+D.getUTCDate()+D.getUTCHours();c[ac](s); $('#article-full-content_'+post_id+' > div[id ^= "M367441ScriptRootC281457"]>iframe').attr('style','display:none !important;'); } } function myUpcharWidget(){ var time = new Date().getTime() / 1000;var dataString='t='+parent.document.title+'&u='+parent.location.href+'&ord='+ time; jQuery.ajax({url: 'https://www.myupchar.com/widget/index',type: "GET",dataType: 'text',data: dataString,cache: false,success: function (response_data) {jQuery('.myupchar_img').attr("src",response_data);jQuery('.myupchar_img').css("margin-top","0px");},error: function(response_data) {jQuery('.myupchar_img').attr("src",response_data);jQuery('.myupchar_img').css("margin-top","0px");} }); }

View original post here:
On World Sight Day 2019, start the healthy habit to exercise your eyes daily - Firstpost

Read More...

Greater London Fund for the Blind rebrands as the Vision Foundation – AOP

October 10th, 2019 9:46 am

The Greater London Fund for the Blind has rebranded as the Vision Foundation and announced a five-year strategy to coincide with World Sight Day today (10 October).

The charitys strategy outlines a plan to make London more accessible for people living with sight loss.

It explained that the rebrand and strategy has been launched in response to the growing problem of sight loss in London and the decrease in opportunities for people living with a visual impairment.

CEO of the Vision Foundation, Olivia Curno, said: Sight loss costs London 2.7bn each year, which equates to 300 per Londoner. Behind every single pound of economic cost there is a human story of isolation, poverty, discrimination and exclusion. This is the challenge facing the Vision Foundation in the 21st century.

In a survey of 111 adults living with sight loss carried out by the Vision Foundation, 50% stated that they did not feel like an equal citizen in London, compared to 40% who did with 10% who did not respond.

The Vision Foundation highlighted that 28% of respondents said that better education and awareness about sight loss would have the biggest impact on their quality of life.

When respondents were asked if they felt that London is open to visually impaired people in terms of employment, 33% said yes and 57% said no.

In addition, 80% reported having had mental health issues as a result of their sight loss.

In a YouGov survey of 2203 adults commissioned by the Vision Foundation, 6% of people said they thought that someone who is blind would be able to do all of their job, while 26% said they would be able to do some of their job and 60% said a blind person would not be able to do any of their job. When asked the same question about people who live with partial sight loss, the figures rose to 16%, 48% and 29% respectively.

Chair of trustees at the Vision Foundation, Anna Tylor, said: Its hugely disappointing that so many blind and partially sighted Londoners are not living their best lives and are not able to contribute in the way they could to the economic and cultural life of our great city.

Its an unacceptable position and as a charity we're changing the way we do business to try and address it. Step by step, we are proving that things can be different. But we are under no illusion that our task will be easy. It is only with the help of the rest of London that people who are blind and partially sighted can be active, equal members of society and able to live life to the full, she added.

Its new Londons Sight Loss Charity strapline is designed to highlight the charitys purpose and distinguish it from other sight loss organisations, the Vision Foundation explained.

Speaking about the name change, Ms Curno said: Our new name was chosen after a lengthy consultation with blind and partially sighted people who told us that our old name was old-fashioned, unfriendly and bureaucratic. The Vision Foundation describes an optimistic future and presents what we do and who we help, ensuring our work is better recognised and understood.

More:
Greater London Fund for the Blind rebrands as the Vision Foundation - AOP

Read More...

GenSight Biologics Reports Evidence of GS010 DNA Transfer to Contralateral Eye of Primates Unilaterally Injected With GS010 Gene Therapy – BioSpace

October 10th, 2019 9:46 am

Oct. 9, 2019 05:30 UTC

PARIS--(BUSINESS WIRE)-- Regulatory News:

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191008006015/en/

Figure 1: Presence of GS010 DNA in the visual and cerebral systems of test monkeys (Graphic: Business Wire)

GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today reported positive proof of GS010 DNA transfer from one eye to the other eye following unilateral intravitreal injection of primates. In a non-clinical study to investigate the local biodistribution of GS010, tissue samples from the non-injected eye of monkeys that had been unilaterally injected with GS010 were found to contain GS010 DNA three months after injection, indicating the expression of the therapeutic gene in the contralateral eye

These results join a growing body of evidence suggesting the two eyes communicate not only in disease, but also in response to treatment, said David J. Calkins, PhD, ODay Professor, Vice Chair and Director for Research Vanderbilt Eye Institute, Vanderbilt University Medical Center, Nashville, Tennessee, United States. With the new understanding these results provide, we can move forward with more precise treatments.

Performed by CiToxLAB France, a leading CRO for preclinical research, the study was initiated by GenSight to investigate potential mechanisms behind the unexpected contralateral effect seen in two of GS010s Phase III trials, REVERSE and RESCUE. As previously reported, both trials, which this year completed the two-year follow-up of patients unilaterally injected with GS010, documented sustained bilateral improvements in LogMAR mean visual acuity. The contralateral effect did not conform to expectations for gene therapies administered to only one eye.

The CiToxLAB study uses a purpose-bred species of monkeys, which is favored by scientists and accepted by regulatory bodies due to physiological similarities with humans. For testing at three months, a control monkey was given an intravitreal injection of saline solution in its right eye and was not injected in its left eye. Three test monkeys were given an intravitreal injection of GS010 in their right eyes and not injected in their left eyes. The dosage of GS010 was calibrated to be the allometric equivalent of that used in the GS010 Phase III trials. Three months after the injection, tissues from the right and left eyes were sampled and tested using a qPCR test which had been validated in a dedicated prior study. The highly sensitive and accurate test contains a protocol that specifically targets a portion of the GS010 DNA and can detect the GS010 DNA matrix.

As expected, the qPCR test did not detect the GS010 DNA in any of the tissue samples from the control monkey unilaterally injected with saline solution. Also as expected, the test was able to detect, and in many cases, quantify the presence of GS010 DNA in tissue samples from GS010-injected right eye. Remarkably the qPCR test was also able to detect, and even quantify, viral DNA vector in the contralateral eye, which had received no injection.

Note: qPCR test used to detect GS010 DNA was validated in a dedicated study conducted prior to the monkey study. The graph depicts the number of monkeys whose tissues contained DNA that were within the sensitivity of the test to detect. In some cases, the levels were above the quantifiable threshold.

DNA was detected and quantified in the anterior segment, the retina, as well as the optic nerve of the non-injected contralateral eye. In addition, DNA was detected and quantified in the optic chiasm, suggesting that the anatomic route taken by the viral vector DNA from the treated eye to the non-treated eye was via the optic nerves and chiasm.

The identification of viral vector DNA in the contralateral uninjected eye is an important observation with broader relevance to the design of gene therapy trials for optic neuropathies, noted Dr. Patrick Yu-Wai-Man, Senior Lecturer and Honorary Consultant Ophthalmologist at the University of Cambridge, Moorfields Eye Hospital, and the UCL Institute of Ophthalmology, London, United Kingdom. Although the non-human primate study was not designed to determine the underlying mode of transfer, the presence of viral vector DNA in the optic chiasm and optic nerve of the contralateral uninjected eye points towards a possible diffusion pathway. Further experimental work will clarify these interesting findings.

We are excited about these scientifically significant results, commented Bernard Gilly, Co-founder and Chief Executive Officer of GenSight. Moreover, they vindicate the companys position that the unexpected bilateral improvements seen in the REVERSE and RESCUE trials have a solid scientific basis. The results help provide a compelling argument in support of GS010s marketing authorization application.

GenSight is working with its panel of scientific experts to prepare the findings for submission to a peer-reviewed journal later this year.

Dr. Yu-Wai-Man will discuss these findings when he presents RESCUE results at the 2019 annual meeting of the American Academy of Ophthalmology in San Francisco, CA:

Session Date: Sunday, October 13Paper Session: OP04 Neuro-Ophthalmology Original PaperSession Time: 2:00 PM to 3:15 PMLocation: South 152Presenter: Patrick Yu-Wai-Man, FRCOphth MBBS PhDPresentation time: 3:00 p.m.

About GenSight Biologics

GenSight Biologics S.A. is a clinical-stage biopharma company focused on discovering and developing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders. GenSight Biologics pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence (MTS) and optogenetics, to help preserve or restore vision in patients suffering from blinding retinal diseases. GenSight Biologics lead product candidate, GS010, is in Phase III trials in Leber Hereditary Optic Neuropathy (LHON), a rare mitochondrial disease that leads to irreversible blindness in teens and young adults. Using its gene therapy-based approach, GenSight Biologics product candidates are designed to be administered in a single treatment to each eye by intravitreal injection to offer patients a sustainable functional visual recovery.

About GS010

GS010 targets Leber Hereditary Optic Neuropathy (LHON) by leveraging a mitochondrial targeting sequence (MTS) proprietary technology platform, arising from research conducted at the Institut de la Vision in Paris, which, when associated with the gene of interest, allows the platform to specifically address defects inside the mitochondria using an AAV vector (Adeno-Associated Virus). The gene of interest is transferred into the cell to be expressed and produces the functional protein, which will then be shuttled to the mitochondria through specific nucleotidic sequences in order to restore the missing or deficient mitochondrial function.

About Leber Hereditary Optic Neuropathy (LHON)

Leber Hereditary Optic Neuropathy (LHON) is a rare maternally inherited mitochondrial genetic disease, characterized by the degeneration of retinal ganglion cells that results in brutal and irreversible vision loss that can lead to legal blindness, and mainly affects adolescents and young adults. LHON is associated with painless, sudden loss of central vision in the 1st eye, with the 2nd eye sequentially impaired. It is a symmetric disease with poor functional visual recovery. 97% of patients have bilateral involvement at less than one year of onset of vision loss, and in 25% of cases, vision loss occurs in both eyes simultaneously. The estimated incidence of LHON is approximately 1,400 to 1,500 new patients who lose their sight every year in the United States and Europe.

About REVERSE and RESCUE

REVERSE and RESCUE are two separate randomized, double-masked, sham-controlled Phase III trials designed to evaluate the efficacy of a single intravitreal injection of GS010 (rAAV2/2-ND4) in subjects affected by LHON due to the G11778A mutation in the mitochondrial ND4 gene.

The primary endpoint will measure the difference in efficacy of GS010 in treated eyes compared to sham-treated eyes based on BestCorrected Visual Acuity (BCVA), as measured with the ETDRS at 48 weeks post-injection. The patients LogMAR (Logarithm of the Minimal Angle of Resolution) scores, which are derived from the number of letters patients read on the ETDRS chart, will be used for statistical purposes. Both trials have been adequately powered to evaluate a clinically relevant difference of at least 15 ETDRS letters between treated and untreated eyes adjusted to baseline.

The secondary endpoints will involve the application of the primary analysis to bestseeing eyes that received GS010 compared to those receiving sham, and to worseseeing eyes that received GS010 compared to those that received sham. Additionally, a categorical evaluation with a responder analysis will be evaluated, including the proportion of patients who maintain vision (< ETDRS 15L loss), the proportion of patients who gain 15 ETDRS letters from baseline and the proportion of patients with Snellen acuity of >20/200. Complementary vision metrics will include automated visual fields, optical coherence tomography, and color and contrast sensitivity, in addition to quality of life scales, biodissemination and the time course of immune response. Readouts for these endpoints are at 48, 72 and 96 weeks after injection.

The trials are conducted in parallel, in 37 subjects for REVERSE and 39 subjects for RESCUE, in 7 centers across the United States, the UK, France, Germany and Italy. Week 96 results were reported in 2019 for both trials, after which patients were transferred to a long-term follow-up study that will last for three years.

ClinicalTrials.gov Identifiers: REVERSE: NCT02652780RESCUE: NCT02652767

About REFLECT

REFLECT is a multi-center, randomized, double-masked, placebo-controlled study to evaluate the safety and efficacy of bilateral injections of GS010 in subjects with LHON due to the NADH dehydrogenase 4 (ND4) mutation.

The trial planned to enroll 90 patients with vision loss up to 1 year in duration and will be conducted in multiple centers in Europe and in the US.

In the active arm, GS010 will be administered as a single intravitreal injection to both eyes of each subject. In the placebo arm, GS010 will be administered as a single intravitreal injection to the first affected eye, while the fellow eye will receive a placebo injection.

The primary endpoint for the REFLECT trial is the BCVA reported in LogMAR at 1-Year post-treatment in the secondaffected/notyetaffected eye. The change from baseline in secondaffected/notyetaffected eyes receiving GS010 and placebo will be the primary response of interest. The secondary efficacy endpoints include: BCVA reported in LogMAR at 2-Years post-treatment in the secondaffected/notyetaffected eye compared to both placebo and the firstaffected eye receiving GS010, OCT and contrast sensitivity and quality of life scales. The first subject was treated in March 2018, and enrolment was completed in July 2019, ahead of schedule.

ClinicalTrials.gov Identifiers: REFLECT: NCT03293524

View source version on businesswire.com: https://www.businesswire.com/news/home/20191008006015/en/

View original post here:
GenSight Biologics Reports Evidence of GS010 DNA Transfer to Contralateral Eye of Primates Unilaterally Injected With GS010 Gene Therapy - BioSpace

Read More...

I Tried to Avoid the Eye Doctor With This Gadget and Failed Miserably – Gizmodo

October 10th, 2019 9:46 am

The unnecessarily complicated story of how an irresponsible adult got new pair glasses. Photo: Victoria Song (Gizmodo)

You should go to your eye doctor more than once every twelve years. Thats called being an adult and having good common sense. I, however, am bad at adulting and somehow found myself in my early thirties, wearing a severely outdated prescription. How bad was it? I was at the point where after leaving the subway, I needed to take out my iPhone and use the camera to zoom in on the next street to see what direction I should walk in.

An at-home test to check your prescription

Checking my prescription in my pajamas. Can order glasses online via app.

I still had to go to the eye doctor. The doctor's prescription was more accurate.

Thats why I jumped at the chance to check out EyeQue VisionCheck. For $70, you can ostensibly check your vision via an optical smartphone attachment and then actually order glasses online. As someone with phone anxiety and a deep existential hatred of doctors officesits a dream come true. Initially, I was wary that something like this could work to any degree. When I saw EyeQue had won the CES 2019 Innovation Award, I felt somewhat reassured that the worst that could happen was I got a bunk pair of glasses. While some CES Innovation Awards border on wacky (This Umay Rest Thermal Meditation band?), its also awarded to legitimate products like the Lenovo Yoga Book C930 or the Sony WH-100xM3 headphones.

The idea behind the EyeQue is its essentially a miniature, phone-based version of that large contraption at your eye doctors officean autorefractor. You know, that hulking machine you sit at and stare at a picture of a blurry house or hot air balloon until it gradually comes into focus. (Its used to estimate your prescription, before further refining it with a phoropter while you look at a Big E chart.)How it works is you first download the EyeQue VisionCheck app for iOS or Android, and strap the mini refractometer to your phone screen. Then you stick it to your eye, and what you end up seeing are two discrete linesone green, one red. Your job is essentially to merge the green and red lines together into one yellow one, with the help of some touch sensors on the side of the device. You do this about eight times per eye, which altogether make up one test. This somehow measures how light is refracted into your eye and voil, the app spits out a prescription.

The second half of the test involves a pair of plastic glasses to measure your pupillary distanceor, the distance between your pupils. You basically stick the glasses on, take a selfie with the app, and then mark the center of your pupils and the glasses bridge with some little green xs. If youre used to getting your glasses from a physical store, its not a measurement youve probably heard of. Conversely, online services like Warby Parker, GlassesUSA, and Zenni Optical all rely on pupillary distance to give you the best possible fit.

If this sounds wacky, it kind of is. You will look stupid. I most definitely did. To learn how to properly take the test, I had a Skype demo with the EyeQue folks. In the process, I got a fair number of looks from bewildered coworkers. It also takes about 15 minutes to really get a feel for what youre supposed to do, thought there are tutorials within the app to help. I also found the sensors to be a bit difficult to press, meaning theyre probably not the best for the elderly or people with limited mobility in their hands. EyeQue recommended you take at least three tests for accuracy, but since itd been so long since my last eye test, they advised I take the test an additional three times just to be safe. All in all, it took about an hour for me to finish 6 tests. Once that was done, I put in an order for a new pair of glasses, which arrived about two weeks later.

As I expected, years of sitting hunched over my computer screen meant my eyesight had deteriorated. My old prescription jumped from -7 in each eye to -7.75. The cylindrical measurement for my right eye went from -1.25 to -2.25. My axis measurement in the right eye stayed about the same, going from 170 to 164. My left eye, however, worsened from 10 to 29.

But how accurate were these readings really? Sure, when I put on the pair Id ordered through EyeQue, my initial thought was Oh, so thats how faraway things are supposed to look. That said, small print or distant signs were still blurry. If I closed my left eye, things got way fuzzier. Many moons ago, a doctor told me my eyes were tragically bad thanks to severe astigmatism. That made me wonder if the reason my vision was still blurry was because EyeQue couldnt handle eyes as bad as mine. To find out I had to suck it up, put my health insurance to good use, and go to an eye doctor.

So off I went. In addition to finding out I had many, many things wrong with my eyes (dont sleep with contacts in), the doctor also told me to throw the EyeQue in the garbage. After a vision test, she determined my prescription was in fact, -9 in the right eye and -8 in the left. Other than that the cylindrical and axis measurements were relatively similar. I was still -2.25 and 165 in the right, and -1.25 and 15 in the left. That didnt seem all that different to me, but my eye doctor thought otherwise. Looking at the EyeQue readings, she noted that it failed to catch my right eye was much worse than my lefta fact I vaguely remembered my childhood doctor telling me as well. To drive the point home, she had me try and read letters off a chart with the prescription she wrote for me, and then with the one EyeQue had given. Things were undeniably much clearer with my eye doctors prescription. (That said, my right eye is so bad my doctor said its unlikely Ill ever get 20/20 vision, even with glasses.)

In my doctors opinion, something like EyeQue would probably be fine for someone with a low prescription, without more complex issues like astigmatism. She was also quick to point out that it would not be a good idea for contacts, and strongly emphasized that devices are unable to diagnose serious conditions like macular degeneration, cataracts, or glaucoma. Not that EyeQue claims it can do any of those thingsit doesnt. But I can see how it might be easy to conflate vision tracking with overall eye health. Similarly, people sometimes hail the Apple Watch as a device that might save your life simply because it can now monitor for irregular heart rate or arrhythmia. However, just because an Apple Watch doesnt sound an alarm, doesnt mean youre free and clear. In the same vein, if EyeQue doesnt detect worsening vision, that doesnt mean your eyes are in perfect health.

Finally, while EyeQue did win a CES Innovation Award, thats not a substitute for something like FDA clearance. Sure, it sounds impressive but winning an award isnt the same thing as earning a certification from a government agency.

I went back to EyeQue with my eye doctors concerns, and my different results. An EyeQue spokesperson emailed me back, writing, Theres actually no magic number. Eye doctors generally consider variance up to 0.5 diopters as acceptablemeaning if you visited a different ophthalmologist on the same day, you would likely get a slightly different prescription.

EyeQue also said that the results I got from its test was comparable to the one my eye doctor gave me. That struck me as odd, given my eye doctors reaction. They also told me that 90 percent of their customers surveyed said glasses they ordered via EyeQue performed the same (33 percent) or better (53 percent) than previous pairs. Its true the EyeQue glasses I ordered were better than my old ones. Its also true the glasses I got with my eye doctors prescription were even better. Vision is important, and it stands within good reason that Id want the best possible prescription for my money.

EyeQue is designed to be used between doctors visits to get more people engaged with their eye health. The convenience of having these devices at home means you can take a quick test any time you feel your vision, or your familys vision has changed, the spokesperson added.

That last bit sounds fair. Except, if I still have to go to my eye doctor, who will likely check my vision each time I go, then what is the point again? Savings? An in-store prescription check at Warby Parker is $40, and you could probably find local optometrists for similar prices. Thats relatively affordable even if you dont have insurance. If you have vision insurance, a routine eye exam is probably covered to an extentmy copay was $30. Both cases are cheaper than the $70 EyeQue. If the actual cost of frames and lenses is the issue, well EyeQue isnt really going to solve that. Im not convinced its a good means of further engaging with your health either. After all, it took 12 years to feel my vision had changed and that maybe I needed a checkup. Plus, it might just be my doctor, but she didnt find my EyeQue results that compelling or helpful.

So if not savings, is it convenience? While I found EyeQue easier to use the more tests I did, I wouldnt call it easier than telling my eye doctor whether or not something was clearer or blurrier. Sure, it was cool that I could spend an hour at home in my jammies, staring into a tube attached to my phone. But that hour roughly added up to the amount of time I spent filling out forms, waiting, and finally being examined at the doctors. Start to finish, ordering a pair of glasses through EyeQue and ordering them on my own took about the same amount of time.

The most valuable thing I got from this experience was it forced me to go to the eye doctor. EyeQue would probably say that was the goal all along. I could see this as being useful for anyone who lives in a remote area, where its not at all easy to get to an eye doctor. It might also come in handy for the disabled. Or if your only pair of glasses broke and you just needed a new pair of glasses quickly without fussing with insurance or finding an optometrist.

That said, if the main reason you havent been to the eye doctor is lazinessyou really dont need to shell out $70 for the privilege of taking eye exams at home. Especially not when there are cheaper options available. Dont be like me. Suck it up. Go get your eyes checked out.

Follow this link:
I Tried to Avoid the Eye Doctor With This Gadget and Failed Miserably - Gizmodo

Read More...

Opening the doors for the region’s blind residents – Concentrate

October 10th, 2019 9:46 am

What would you do if you suddenly lost your sight?

A new project aimed at helping newly-blinded Great Lakes Bay Region residents prepare for the change that experiencing loss of sight lives brings is in the works.

I am the organizer of this project, because years ago, my heart was broken when I returned to Midland after an eight-year absence. Blind all my life, I realized that, although I was born totally blind and learned many valuable skills as a young child, most people who have visual impairments have become so because of eye diseases that began when they were older.

A new project aimed at helping newly-blinded people in the Great Lakes Bay Region prepare for the change that experiencing loss of sight lives brings is in the works.Able to see all their lives; now, they cant go anywhere without someone leading them, they cant read the paper, use a computer or watch TV. Perhaps they struggle to cut their food, they spill their drinks or trip over things around the house.

Sometimes the newly blind dont know whom to talk to, what they need to learn or if they can do any of the everyday things they used to do. And most communities dont have enough of the specialized services and equipment they need.

My new project, called Life After Blindness, is an attempt to help people determine what their future lives will be like. When the ophthalmologist says Sorry; theres no more we can do, I can visit their houses or talk to them on the phone.

I can fully attest to the fact that life need not be over; these people have the power to choose what life with vision loss will be like.

It all can be done, those with sight loss just need to learn some adaptations that may have to be made from their previous way of doing activities.Sometimes, when I first talk to someone with sight loss, he or she says, I dont know what to do. I dont know who to talk to. One woman said she had made the rounds of local pharmacies and had not found a single white cane for sale.

Typically, most adaptive devices for people with visual impairments are available only through the mail. White canes must be ordered to fit a persons height, and canes are made in increments of two inches in length.

Another resource that is available is working with a service dog. But before getting the aid of a service animal, a person should have white-cane training to know the basics of getting around before getting a dog. Besides, a young dog is strong and speedy and probably will try to take control away from the master until they learn to work together.

Most adaptive devices for people with visual impairments are available only through the mail.Here are some of the questions I often ask people about their life plans after blindness: Do you want to learn to use a computer? Do you want to know how to turn on speech in a cell phone and understand how to give it commands? Do you want to learn Braille, and if you do, why? (Braille is English, just like print is, but many characters have multiple uses and there are many contractions think of them as being like the &sign.) Do you want to cook and clean your house independently? That means your stove, microwave, washer and dryer need tactile markings to choose settings. Do you want to continue hobbies such as sewing, woodworking or carpentry? You might need needle threaders and Braille sewing patterns, and a bit of safety training to continue using tools.

It all can be done, those with sight loss just need to learn some adaptations that may have to be made from their previous way of doing activities.

Cheryl Wade started Life After Blindness as a personal passion after seeing the need.One man told me he has definite goals: He wants to hunt, hike and fish the way he used to, and he wants to go to one of his favorite places in Oscoda. So, right now, I am looking for a volunteer to drive him and to describe the lay of the land. Another woman needs someone to teach her how to use an Android phone with the speech turned on, and I cant find anyone locally who knows how to do that.

There are many adaptations that can assist the newly blind. Audible books available from a free lending library, computers that read words on the screen audibly and aid in screen navigation, movies that describe whats happening on the screen.

There is free training through the State of Michigan to help people learn to travel with a white cane, use computers and read Braille. There is bold lined paper and tactile lined paper for writing print. There are options to make Android and iPhones speak out of the box and dozens of gadgets for all kinds of tasks. But users might need specialized training thats not available locally.

A great resource that is available is working with a service dog once a person has learned adaptations on their own.Services in the region include ride services, meals, transportation and help determining home modifications,exercise facilities,and art classes. The Disability Network of Mid-Michigan has a kit filled with adaptive devices that people experiencing sight loss might need, and the organization can provide advocacy and help people adjust to new disabilities.

But there is almost no one who knows how to adapt these events for persons with little or no vision and who have not had training to help them get what they need. Having a teacher point a finger and say the easels are over there doesnt do it for a blind person. Designing art projects that largely are based on the sense of touch is challenging. And how does a person with almost no vision navigate a large exercise facility with multiple strength training machines?

Cheryl Wade and her dog out for a walk in Midland.Thats why I hope to find volunteers who can orient folks to their surroundings using cardinal directions, audible or tactile landmarks to get around a building, or gauging distances and the time it takes to get from one place or thing to another. Perhaps sight-impaired people need to grab a sighted persons elbow to get around a store or an exhibit. We have teachers and counselors from the state who can help train people to adjust to blindness, but they work in multiple counties and cant drop everythingwhen someone has a question such as, I dont know how to make a Braille z. I could answer that question.

As a trained rehabilitation (disability and employment) counselor with a masters degree from Michigan State University, I also am prepared to talk about the psychological changes that a new, expensive, pain-in-the-neck disability might cause. Withdrawal, denial and acceptance are part of the grieving process, and the negative emotions might return from time to time.

Life After Blindness, is an attempt to help people determine what their future lives will be like.I am working with a group of area residents who have sight loss and who meet on the last Saturday of almost every month for a delicious, free lunch and a presentation by a speaker. The group meets at Aldersgate United Methodist Church, 2206 Airfield Lane, and the meeting lasts from 11:30 a.m. to 1:00 p.m. Rides are available. To sign up, call Dick Skochdopole, (989) 835-6433.

At this early stage, I am working to meet people who are blind and find local service clubs to provide us with drivers, guides and donations. With a few hundred dollars a year, I hope to buy equipment such as Braillers and accessible aids and games. I also the ability and connections to acquire used equipment.

"I can fully attest to the fact that life need not be over."I hope to have a food-cutting workshop in which people can feel things like cake or meat with their hands, then figure out how to hold a knife so it will cut rather than having the end stick up in the air. By taking the time for this activity, people could practice cutting in a straight line, then cutting perpendicular to that line. As a member of Michigan Ski for Light a group for blind and mobility-impaired skiers I hope to acquire donated ski equipment and get some of my new friends on skis next year.

If youor someone you know has been impacted by vision loss, please know that life isnt over and there are resources and people to help.

For more information or to inquire about being a volunteer for someone with vision loss, contact me at (517) 574-6898 or wadecheryl42@gmail.com.

See the rest here:
Opening the doors for the region's blind residents - Concentrate

Read More...

Omega Launches New Collection of Luxury Eyewear with Marcolin Group – InvisionMag

October 10th, 2019 9:46 am

(PRESS RELEASE) DUBLIN In support of World Sight Day, Horizon Therapeutics plc (Nasdaq: HZNP) and Prevent Blindness launched a campaign that brings together the voices of the thyroid eye disease (TED) community to educate the public on how TED can damage vision and encourage people who are living with TED to put their vision first by sharing their experiences, monitoring their symptoms and finding the right doctor. World Sight Day is an internationally recognized awareness day designed to focus attention on blindness and vision impairment. This years dialogue emphasizes Vision First, with a call to the community to make vision a priority.

Now through Oct. 31, 2019, Horizon will donate $1 (up to $10,000) to Prevent Blindness every time someone texts EYE to 56512. The campaign also invites the TED community to visit http://www.MyTEDStory.com to share how they have seen TED affect vision whether it be from experiencing it personally, or watching a friend, loved one or patient endure it. Select stories will be compiled and shared on social media to help people who are living with TED, healthcare professionals and the general public better understand the disease. Spotting the signs and symptoms of TED early can help decrease the chances of permanent eye damage. People who are at risk for TED, including those with Graves disease, are encouraged to pay attention to changes in their eyes such as pain, redness, light sensitivity, bulging, blurry vision and double vision and visit an ophthalmologist or oculoplastic surgeon to get an eye exam.

According to the World Health Organization, approximately 80 percent of all vision impairment across the globe is considered avoidable this statistic is both shocking and unacceptable, said Jeff Todd, president and CEO, Prevent Blindness. As a part of our sight-saving mission, we are thrilled to partner with Horizon to raise awareness about TED and inspire patients to actively monitor and successfully manage their symptoms.

TED is a serious, progressive and vision-threatening autoimmune disease.1,2 TED begins with active TED that may last for up to three years, after which damage to the eyes can be irreversible.1,3 Common symptoms include light sensitivity, eye grittiness, bulging eyes and double vision, among others all of which can reduce a persons independence, ability to work and self-confidence.1,4 As TED progresses, it can cause long-term, irreversible damage. Effective management of TED requires early diagnosis and active monitoring to identify the best opportunity for medical intervention.1 Patients who suspect that they may have TED should visit an eye specialist, such as an ophthalmologist or oculoplastic surgeon, to have their eyes examined. To learn more about TED, visit the new Prevent Blindness web resource and visit http://www.ThyroidEyes.com to sign up to receive information about TED.

At Horizon, weve made it our priority to better understand the needs of the TED community, said Matt Flesch, vice president, communications and patient advocacy, Horizon. Through conversations with patients, caregivers and healthcare professionals, weve heard how this disease can impair vision making it difficult to do the things we often take for granted, like drive, walk up or down stairs alone and read. By working together with Prevent Blindness, we hope to multiply our efforts and reach even more people with the TED education and support they need to speak up and be good advocates for their eye health.

To learn more about World Sight Day and other ways to get involved, visit the website for The International Agency for the Prevention of Blindness.

Original post:
Omega Launches New Collection of Luxury Eyewear with Marcolin Group - InvisionMag

Read More...

Eurecon Verlag GmbH: 20th Pharma Trend Image & Innovation Awards The Winners and Runner-ups – Business Wire

October 10th, 2019 9:45 am

MUNICH--(BUSINESS WIRE)--An interdisciplinary jury of ten evaluated the applications by medical startups in the categories biotechnology, medical technology and digital health. The products and projects ranked among the top 3 received the Most Innovative Product Award. The discipline-specific awards were presented during the Pharma Trend Image & Innovation Awards, which took place on September 17, 2019, at the German Museum in Munich, this year marking the 20th award ceremony.

The jury assessed the submitted product and project applications based on criteria such as the benefit for the patients, the innovative content, efficiency in application and the transition to standard care. In 2019, the following companies received the Most Innovative Product award:

Digital health: BOCAhealth, the body fluids manager of the future

Body fluids disorders (dehydration or its opposite, chronic fluid retention) are a common and risky issue in many clinical situations, especially in heart failure, chronic kidney disease and elderly patients. It is estimated that every other patient is released from hospital with a hydration problem, and their 1-year mortality is up to 30%. Inside the hospital ward, the patients hydration status is checked through the inaccurate fluid balance (inflow of infusions outflow of urine). At home the patients use weight scales that do not allow an accurate assessment of body water changes either. So far, there is no accurate, easy to use, digital and versatile solution for both hospital and home monitoring.

BOCAhealth is a portable bioimpedance device connected with a smartphone application that easily measures the patients hydration and nutrition status and estimates their cardiac output and systemic vascular resistance. The BOCAhealth software provides doctors with a real-time risk prediction score based on artificial intelligence to guide the infusion and medical therapy.

BOCAhealth is the first body fluid composition analyzer that combines portability, accuracy and a risk predictor score based on artificial intelligence. These benefits convinced the jury to grant BOCAhealth the award for the Most Innovative Product. The award was accepted by the CEO and founder Dr. Allesandro Faragli.

Medical technology: Surge-on Medical, Freedimensional surgical instruments to empower surgeons

Founded in 2015 in the Netherlands, Surge-on Medical has developed the next generation of minimally invasive surgical instruments. Through cable-free technologies, they have created freedimensional instruments that provide better access to surgical areas and replace current pre-bent instrumentation, while complying with current and future FDA and European regulation. Surge-on Medical has been granted four international patents which make minimally invasive instruments steerable, detachable and cleanable. The company is currently active in arthroscopy, laparoscopy and robotic surgery, but it is also preparing to expand to additional surgical fields to keep empowering surgeons. It aims to become the worldwide leader in the development of minimally invasive instruments.

The Most Innovative Product award for the second place was accepted by Dr. Tim Horeman, CTO of Surge-on Medical.

Biotechnology: Letermovir (Prevymis) by AiCuris

AiCuris has developed a new agent against the human cytomegalovirus (HCMV), which occurs around the world. More than half of the global population are chronically infected with the virus, but only patients with a weakened or lacking immune system are at risk of serious illness or even death. The new agent Letermovir inhibits an enzyme within the virus and thus prevents its spread without damaging the host cell. This allows very good tolerability, which for the first time enables prophylactic life-saving therapy.

Letermovir was initially developed, and has already been successfully applied, for HCMV prophylaxis in patients who have undergone stem cell and bone marrow transplantation. Following a successful phase 3, Letermovir was approved in the USA, Canada, Japan and other countries as part of a process of introducing the drug to the global market. In the future, Letermovir will also benefit organ transplant recipients, AIDS patients and new-borns. The drug has been available from German pharmacies since 2018 under the brand MSD brand name Prevymis. It was very well received by the medical community and significantly exceeds revenue expectations in the first months of sales.

AiCuris was founded in 2006 as a spin-off from what was then Bayer research division on infectious diseases. Since then, the company has been researching and developing new drugs to treat virological and bacteriological conditions. In 2012, AiCuris was able to conclude a much-noticed license agreement with MSD concerning HCMV drugs.

Dr. Holger Zimmermann, CEO of AICuris, accepted the third-place award The Most Innovative Product on behalf of his company.

A successful jubilee ceremony

The patron to the jubilee awards ceremony was the Bavarian Permanent Secretary for Health, Melanie Huml. Around 140 invited decision-makers from the pharmaceuticals industry and health care communications agencies attended the event. Keynote speakers were Dr. Peter-Andreas Lschmann, board member of Bio Deutschland (the German biotechnology industry association), and Dr. Thomas Rodenhausen, board member of Harris Interactive AG. The host for the night was Tamara Sedmak, who regularly presents on TV channels including Sat 1, n-tv and N24.

For more information on Pharma Trend, see https://pharma-trend.com/en/pharma-award/ https://youtu.be/ZTnvSoPeZfQ

Read more from the original source:
Eurecon Verlag GmbH: 20th Pharma Trend Image & Innovation Awards The Winners and Runner-ups - Business Wire

Read More...

The 2019 Nobel Prize in Medicine awarded for research in cellular responses to oxygen – World Socialist Web Site

October 10th, 2019 9:45 am

The 2019 Nobel Prize in Medicine awarded for research in cellular responses to oxygen By Benjamin Mateus 10 October 2019

In the course of a lifetime, the human heart will beat more than three billion times. We will have taken more than 670 million breaths before we reach the end of our lives. Yet, these critical events remain unconscious and imperceptible in everyday life, unless we exert ourselves, such as running up several flights of stairs. We quickly tire, stop to take deep breaths and become flushed.

With the deepening comprehension by medical science of how our bodies work, we have come to better understand the fundamental importance of oxygen to life. Every living organism relies on it in one form or another. However, how cells and tissues can monitor and respond to oxygen levels remained difficult to elucidate. It has only been late in the 20th century with advances in cellular biology and scientific instrumentation that these processes have finally been explained.

On Monday, the 2019 Nobel Prize in Physiology or Medicine was awarded jointly to three individuals: William G. Kaelin, Jr., Sir Peter J. Ratcliffe, and Gregg L. Semenza. Specifically, their discoveries helped elucidate the mechanisms for lifes most basic physiologic processes.

They were able to discover how oxygen levels directly affect cellular metabolism, which ultimately controls physiological functions. More importantly, their findings have significant implications for the treatments of conditions as varied as chronic low blood counts, kidney disease, patients with heart attacks or stroke and cancers. One of the hallmarks of cancer is its ability to generate new blood vessels to help sustain its growth. It also uses these oxygen cellular mechanisms to survive in low oxygen environments.

Dr. William G. Kaelin Jr. is a professor of medicine at Harvard University and the Dana-Farber Cancer Institute. The main focus of his work is on studying how mutations in what are called tumor suppressor genes lead to cancer development. Tumor suppressor genes are special segments of the DNA whose function is to check the integrity of the DNA before allowing a copy of itself to be made and undergo cell division, which prevents cells from propagating errors. Cellular mechanisms are then recruited to fix these errors or drive the cell to destroy itself if the damage is too severe or irreparable.

His interest in a rare genetic disorder called Von Hippel-Lindau disease (VHL) led him to discover that cancer cells that lacked the VHL gene expressed abnormally high levels of hypoxia-regulated genes. The protein called the Hypoxia-Inducible Factor (HIF) complex was first discovered in 1995 by Gregg L. Semenza, a co-recipient of the Nobel Prize. This complex is nearly ubiquitous to all oxygen-breathing species.

The function of the HIF complex in a condition of low oxygen concentration is to keep cells from dividing and growing, placing them in a state of rest. However, it also signals the formation of blood vessels, which is important in wound healing as well as promoting the growth of blood vessels in developing embryos. In cancer cells, the HIF complex helps stimulate a process called angiogenesis, the formation of new blood vessels, which allows the cancer cells to access nutrition and process their metabolic waste, aiding in their growth. When the VHL gene is reintroduced back into the cancer cells, the activity of the hypoxia-regulated genes returns to normal.

Dr. Gregg L. Semenza is the founding director of the vascular program at the Johns Hopkins Institute for Cell Engineering. He completed his residency in pediatrics at Duke University Hospital and followed this with a postdoctoral fellowship at Johns Hopkins. His research in biologic adaptations to low oxygen levels led him to study how the production of erythropoietin (EPO) was controlled by oxygen. EPO is a hormone secreted by our kidneys in response to anemia. The secretion of EPO signals our bone marrow to produce more red blood cells.

His cellular and mouse model studies identified a specific DNA segment located next to the EPO gene that seemed to mediate the production of EPO under conditions of low oxygen concentration. He called this DNA segment HIF.

Sir Peter J. Ratcliffe, a physician and scientist, trained as a nephrologist, was head of the Nuffield Department of Clinical Medicine at the University of Oxford until 2016, when he became Clinical Research Director at the Francis Crick Institute. Through his research on the cellular mechanisms of EPO and its interaction between the kidneys and red cell production, he found that these mechanisms for cellular detection of hypoxia, a state of low oxygen concentration, were also present in several other organs such as the spleen and brain. Virtually all tissues could sense oxygen in their micro-environment, and they could be modified to give them oxygen-sensing capabilities.

Dr. Kaelins findings had shown that the protein made by the VHL gene was somehow involved in controlling the response to low oxygen concentrations. Dr. Ratcliffe and his group made the connection through their discovery that the protein made by the VHL gene physically interacts with HIF complex, marking it for degradation at normal oxygen levels.

In 2001, both groups published similar findings that demonstrated cells under normal oxygen levels will attach a small molecular tag to the HIF complex that allows the VHL protein to recognize and bind HIF, marking it for degradation by enzymes. If the oxygen concentration is low, the HIF complex is protected from destruction. It begins to accumulate in the nucleus where it binds to a specific section of the DNA called hypoxia-regulating genes, which sets into motion the necessary mechanisms to respond to the low oxygen concentration.

The ability to sense oxygen plays a vital role in health and various disease states. Patients who suffer from chronic kidney failure also suffer from severe anemia because their ability to produce EPO is limited. This hormone is necessary for the stem cells in our bone marrow to produce red blood cells. Understanding how cancer cells utilize oxygen-sensing mechanisms has led to a variety of treatments that targets these pathways. The ability to elucidate these mechanisms offers insight into directions scientists and researchers can take to design or create novel treatments.

The WSWS recently published its 75,000th article. Become a monthly donor today and keep up this vital work. It only takes a minute. Thank you.

See more here:
The 2019 Nobel Prize in Medicine awarded for research in cellular responses to oxygen - World Socialist Web Site

Read More...

Global Cell Isolation Market Will Reach USD 15.16 Billion By 2025 – Daily Market Updates

October 10th, 2019 9:43 am

The leading research firm Zion Market Research published a research report containing 110+ pages on "Cell Isolation Market by Product (Instruments and Consumables), by Cell Type (Animal and Human), by Cell Source (Adipose Tissue, Embryonic/Cord Blood Stem Cells, and Bone Marrow), by Technique (Surface Marker-Based Cell Isolation, Centrifugation-Based Cell Isolation, and Filtration-Based Cell Isolation), by Application (Cancer Research, Biomolecule Isolation, Tissue Regeneration & Regenerative Medicine, Stem Cell Research, In Vitro Diagnostics, and Others), and By End-User (Hospitals & Diagnostic Laboratories, Research Laboratories & Institutes, Biotechnology & Biopharmaceutical Becton, Dickinson, and Company, Thermo Fisher Scientific, Inc., Merck KGaA, Beckman Coulter Inc., Terumo BCT, Bio-Rad Laboratories, Inc., and Others): Global Industry Perspective, Comprehensive Analysis, and Forecast, 20182025", which serves with all-inclusive, highly-effective, and thoroughly analyzed information in a well-organized manner, based on actual facts, about the Cell Isolation Market. The whole information from scratch to the financial and management level of the established industries associated with the Cell Isolation Market at the global level is initially acquired by the dedicated team. The gathered data involves the information about the industrys establishment, type and the form of products it manufactures, annual sales and revenue generation, the demand of the manufactured product in the market, marketing trends followed by the industry, and a lot more important information.

The industry analysts begin their task by compiling this huge pile of information, graphically expressing, anticipating the future market growth, offering the ways to improve the business, and many other important viewpoints explained by them in the Global Cell Isolation Market report.

Request Sample Copy of Cell Isolation Market Research Report @ https://www.zionmarketresearch.com/sample/cell-isolation-market

The Global Cell Isolation Market report elucidates the comprehensive analysis of the market-derived on the basis of regional division:

The report comprises precise analytical information related to market forecasts for several upcoming years. The report also includes the particulars about the valuation of macro and microelements significant for the growth of already established Cell Isolation Market contenders and emerging new companies.

The industries majorly comprise the global leading industries:

Becton, Dickinson, and Company, Thermo Fisher Scientific, Inc., Merck KGaA, Beckman Coulter Inc., Terumo BCT, Bio-Rad Laboratories, Inc.

Request for PDF Brochure of This Report: https://www.zionmarketresearch.com/requestbrochure/cell-isolation-market

Report Brief:

The report covers forecast and analysis for the Global Cell Isolation Market on a global and regional level.

The report includes the positive and negative factors that are influencing the growth of the market.

Detailed information about market opportunities are discussed.

The key target audience for the market has been determined in the report.

The revenue generated by the prominent industry players has been analyzed in the report.

The market numbers have been calculated using top-down and bottom-up approaches.

The Global Cell Isolation Market has been analyzed using Porters Five Forces Analysis.

The market is segmented on the basis of Component, applications, connectivity, and end-user, which in turn bifurcated on the regional level as well.

All the segments have been evaluated based on present and future trends.

The report deals with the in-depth quantitative and qualitative analyses of the Cell Isolation Market.

The report includes detailed company profiles of the prominent market players.

Inquiry more about this report @ https://www.zionmarketresearch.com/inquiry/cell-isolation-market

The Global Cell Isolation Market report also delivers the accurately estimated pattern of CAGR to be followed by the market in the future. The numerous highlighted features and enactment of the Cell Isolation Market are examined based on the qualitative and quantitative technique to deliver the whole scenario of the current and future evaluation in a more effective and better understandable way.

The report covers a forecast and an analysis of the Cell Isolation Market on a global and regional level. The study provides historical data from 2015 to 2018 along with a forecast from 2019 to 2027 based on revenue (USD Billion). The study includes the drivers and restraints of the Cell Isolation Market along with their impact on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the Cell Isolation Market on a global level.

In order to give the users a comprehensive view of the Cell Isolation Market, we have included a competitive landscape and an analysis of Porters Five Forces model for the market. The study encompasses a market attractiveness analysis, wherein all the segments are benchmarked based on their market size, growth rate, and general attractiveness.

For More Information, Read Detail Report Here: https://www.zionmarketresearch.com/report/cell-isolation-market

About Us:

Zion Market Research is an obligated company. We create futuristic, cutting edge, informative reports ranging from industry reports, company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the clients needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to usafter allif you do well, a little of the light shines on us.

Contact Us:

Zion Market Research

244 Fifth Avenue, Suite N202

New York, 10001, United States

Tel: +49-322 210 92714

USA/Canada Toll-Free No.1-855-465-4651

Email: sales@zionmarketresearch.com

Website: https://www.zionmarketresearch.com

Sorry! The Author has not filled his profile.

Read this article:
Global Cell Isolation Market Will Reach USD 15.16 Billion By 2025 - Daily Market Updates

Read More...

Global Stem Cell Therapy Market To Record Impressive Growth, Revenue To Surge To USD 4759.27 Million By 2024 – Industry News Reports

October 10th, 2019 9:43 am

The leading research firm Zion Market Research published a research report containing 110+ pages on "Stem Cell Therapy Market by Type (Allogenic SCs and Autologous SCs) by Therapeutic Application (Musculoskeletal Disorders, Wounds & Injuries, Cardiovascular Diseases, Gastrointestinal Diseases, Immune System Diseases, and Others), by Cell Source (Adipose Tissue-Derived Mesenchymal SCs, Bone Marrow-Derived Mesenchymal SCs, Embryonic SCs, and Other Sources), and by End User (Hospitals and ASCs): Global Industry Perspective, Comprehensive Analysis and Forecast, 2017 2024", which serves with all-inclusive, highly-effective, and thoroughly analyzed information in a well-organized manner, based on actual facts, about the Stem Cell Therapy Market. The whole information from scratch to the financial and management level of the established industries associated with the Stem Cell Therapy Market at the global level is initially acquired by the dedicated team. The gathered data involves the information about the industrys establishment, type and the form of products it manufactures, annual sales and revenue generation, the demand of the manufactured product in the market, marketing trends followed by the industry, and a lot more important information.

The industry analysts begin their task by compiling this huge pile of information, graphically expressing, anticipating the future market growth, offering the ways to improve the business, and many other important viewpoints explained by them in the Global Stem Cell Therapy Market report.

Request a Sample Report, To Get Brief Information About This Report@ http://www.zionmarketresearch.com/sample/stem-cell-therapy-market

The Global Stem Cell Therapy Market report elucidates the comprehensive analysis of the market-derived on the basis of regional division:

The report comprises precise analytical information related to market forecasts for several upcoming years. The report also includes the particulars about the valuation of macro and microelements significant for the growth of already established Stem Cell Therapy Market contenders and emerging new companies.

Some of the leading global leading market players profiles included in this report are:

Anterogen Co., Ltd., RTI SurgicalInc., Pharmicell Co., Ltd., MEDIPOST Co., Ltd., JCR Pharmaceuticals Co., Ltd., Holostem Terapie Avanzate S.r.l., NuVasiveInc., and AlloSource.

Request PDF Brochure to Receive Summary of This Report @www.zionmarketresearch.com/report/stem-cell-therapy-market

Report Brief:

The report covers forecast and analysis for the Global Stem Cell Therapy Market on a global and regional level.

The report includes the positive and negative factors that are influencing the growth of the market.

Detailed information about market opportunities are discussed.

The key target audience for the market has been determined in the report.

The revenue generated by the prominent industry players has been analyzed in the report.

The market numbers have been calculated using top-down and bottom-up approaches.

The Global Stem Cell Therapy Market has been analyzed using Porters Five Forces Analysis.

The market is segmented on the basis of Component, applications, connectivity, and end-user, which in turn bifurcated on the regional level as well.

All the segments have been evaluated based on present and future trends.

The report deals with the in-depth quantitative and qualitative analyses of the Stem Cell Therapy Market.

The report includes detailed company profiles of the prominent market players.

The Global Stem Cell Therapy Market report also delivers the accurately estimated pattern of CAGR to be followed by the market in the future. The numerous highlighted features and enactment of the Stem Cell Therapy Market are examined based on the qualitative and quantitative technique to deliver the whole scenario of the current and future evaluation in a more effective and better understandable way.

The report covers a forecast and an analysis of the Stem Cell Therapy Market on a global and regional level. The study provides historical data from 2015 to 2018 along with a forecast from 2019 to 2027 based on revenue (USD Billion). The study includes the drivers and restraints of the Stem Cell Therapy Market along with their impact on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the Stem Cell Therapy Market on a global level.

In order to give the users a comprehensive view of the Stem Cell Therapy Market, we have included a competitive landscape and an analysis of Porters Five Forces model for the market. The study encompasses a market attractiveness analysis, wherein all the segments are benchmarked based on their market size, growth rate, and general attractiveness.

Detail Information on This Research Report is Available Here:www.zionmarketresearch.com/report/stem-cell-therapy-market

About Us:

Zion Market Research is an obligated company. We create futuristic, cutting edge, informative reports ranging from industry reports, company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the clients needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to usafter allif you do well, a little of the light shines on us.

Contact Us:

Zion Market Research

244 Fifth Avenue, Suite N202

New York, 10001, United States

Tel: +49-322 210 92714

USA/Canada Toll-Free No.1-855-465-4651

Email: [emailprotected]

Website: http://www.zionmarketresearch.com

Sorry! The Author has not filled his profile.

See the rest here:
Global Stem Cell Therapy Market To Record Impressive Growth, Revenue To Surge To USD 4759.27 Million By 2024 - Industry News Reports

Read More...

Global Cell Expansion Market Share to Surpass USD 24921.3 Million By 2024: Zion Market Research – The Industry Today News

October 10th, 2019 9:43 am

The leading research firm Zion Market Research published a research report containing 110+ pages on "Cell Expansion Market: by Product Type (Instruments, Consumables, and Disposables), by Application (Regenerative Medicine and Stem Cell Research, Cancer and Cell-based Research and Other Applications), and by End-user (Research Institutes, Biopharmaceutical and Biotechnology Becton and Dickinson Company, Corning Incorporation, Danaher Corporation, GE Healthcare, Miltenyi Biotec, Merck Millipore, Sigma Aldrich Corporation, Stemcell Technologies, Terumo BCT, Thermo Fischer Scientific Inc. among others., Cell Banks and Other End Users For Different Cell Type(Human Cells and Animal Cells)) Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2017 2024", which serves with all-inclusive, highly-effective, and thoroughly analyzed information in a well-organized manner, based on actual facts, about the Cell Expansion Market. The whole information from scratch to the financial and management level of the established industries associated with the Cell Expansion Market at the global level is initially acquired by the dedicated team. The gathered data involves the information about the industrys establishment, type and the form of products it manufactures, annual sales and revenue generation, the demand of the manufactured product in the market, marketing trends followed by the industry, and a lot more important information.

The industry analysts begin their task by compiling this huge pile of information, graphically expressing, anticipating the future market growth, offering the ways to improve the business, and many other important viewpoints explained by them in the Global Cell Expansion Market report.

Request a Sample Report, To Get Brief Information About This Report@ http://www.zionmarketresearch.com/sample/cell-expansion-market

The Global Cell Expansion Market report elucidates the comprehensive analysis of the market-derived on the basis of regional division:

The report comprises precise analytical information related to market forecasts for several upcoming years. The report also includes the particulars about the valuation of macro and microelements significant for the growth of already established Cell Expansion Market contenders and emerging new companies.

Some of the leading global leading market players profiles included in this report are:

Becton and Dickinson Company, Corning Incorporation, Danaher Corporation, GE Healthcare, Miltenyi Biotec, Merck Millipore, Sigma Aldrich Corporation, Stemcell Technologies, Terumo BCT, Thermo Fischer Scientific Inc. among others.

Request PDF Brochure to Receive Summary of This Report @www.zionmarketresearch.com/requestbrochure/cell-expansion-market

Report Brief:

The report covers forecast and analysis for the Global Cell Expansion Market on a global and regional level.

The report includes the positive and negative factors that are influencing the growth of the market.

Detailed information about market opportunities are discussed.

The key target audience for the market has been determined in the report.

The revenue generated by the prominent industry players has been analyzed in the report.

The market numbers have been calculated using top-down and bottom-up approaches.

The Global Cell Expansion Market has been analyzed using Porters Five Forces Analysis.

The market is segmented on the basis of Component, applications, connectivity, and end-user, which in turn bifurcated on the regional level as well.

All the segments have been evaluated based on present and future trends.

The report deals with the in-depth quantitative and qualitative analyses of the Cell Expansion Market.

The report includes detailed company profiles of the prominent market players.

The Global Cell Expansion Market report also delivers the accurately estimated pattern of CAGR to be followed by the market in the future. The numerous highlighted features and enactment of the Cell Expansion Market are examined based on the qualitative and quantitative technique to deliver the whole scenario of the current and future evaluation in a more effective and better understandable way.

The report covers a forecast and an analysis of the Cell Expansion Market on a global and regional level. The study provides historical data from 2015 to 2018 along with a forecast from 2019 to 2027 based on revenue (USD Billion). The study includes the drivers and restraints of the Cell Expansion Market along with their impact on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the Cell Expansion Market on a global level.

In order to give the users a comprehensive view of the Cell Expansion Market, we have included a competitive landscape and an analysis of Porters Five Forces model for the market. The study encompasses a market attractiveness analysis, wherein all the segments are benchmarked based on their market size, growth rate, and general attractiveness.

Detail Information on This Research Report is Available Here:www.zionmarketresearch.com/report/cell-expansion-market

About Us:

Zion Market Research is an obligated company. We create futuristic, cutting edge, informative reports ranging from industry reports, company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the clients needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to usafter allif you do well, a little of the light shines on us.

Contact Us:

Zion Market Research

244 Fifth Avenue, Suite N202

New York, 10001, United States

Tel: +49-322 210 92714

USA/Canada Toll-Free No.1-855-465-4651

Email: sales@zionmarketresearch.com

Website: http://www.zionmarketresearch.com

Sorry! The Author has not filled his profile.

Read the original:
Global Cell Expansion Market Share to Surpass USD 24921.3 Million By 2024: Zion Market Research - The Industry Today News

Read More...

BEYOND LOCAL: Expert recommends ‘path of cautious optimism’ about the future of stem cell treatment – TimminsToday

October 9th, 2019 3:36 pm

This article, written byKatharine Sedivy-Haley, University of British Columbia, originally appeared on The Conversation and is republished here with permission:

When I was applying to graduate school in 2012, it felt like stem cells were about to revolutionize medicine.

Stem cells have the ability to renew themselves, and mature into specialized cells like heart or brain cells. This allows them to multiply and repair damage.

If stem cell genes are edited to fix defects causing diseases like anemia or immune deficiency, healthy cells can theoretically be reintroduced into a patient, thereby eliminating or preventing a disease. If these stem cells are taken or made from the patient themselves, they are a perfect genetic match for that individual, which means their body will not reject the tissue transplant.

Because of this potential, I was excited that my PhD project at the University of British Columbia gave me the opportunity to work with stem cells.

However, stem cell hype has led some to pay thousands of dollars on advertised stem cell treatments that promise to cure ailments from arthritis to Parkinsons disease. These treatments often dont help and may harm patients.

Despite the potential for stem cells to improve medicine, there are many challenges as they move from lab to clinic. In general, stem cell treatment requires we have a good understanding of stem cell types and how they mature. We also need stem cell culturing methods that will reliably produce large quantities of pure cells. And we need to figure out the correct cell dose and deliver it to the right part of the body.

Embryonic, 'induced and pluripotent

Stem cells come in multiple types. Embryonic stem cells come from embryos which makes them controversial to obtain.

A newly discovered stem cell type is the induced pluripotent stem cell. These cells are created by collecting adult cells, such as skin cells, and reprogramming them by inserting control genes which activate or induce a state similar to embryonic stem cells. This embryo-like state of having the versatile potential to turn into any adult cell type, is called being pluripotent.

However, induced pluripotent and embryonic stem cells can form tumours. Induced pluripotent stem cells carry a particularly high risk of harmful mutation and cancer because of their genetic instability and changes introduced during reprogramming.

Genetic damage could be avoided by using younger tissues such as umbilical cord blood, avoiding tissues that might contain pre-existing mutations (like sun-damaged skin cells), and using better methods for reprogramming.

Stem cells used to test drugs

For now, safety concerns mean pluripotent cells have barely made it to the clinic, but they have been used to test drugs.

For drug research, it is valuable yet often difficult to get research samples with specific disease-causing mutations; for example, brain cells from people with amyotrophic lateral sclerosis (ALS).

Researchers can, however, take a skin cell sample from a patient, create an induced pluripotent stem-cell line with their mutation and then make neurons out of those stem cells. This provides a renewable source of cells affected by the disease.

This approach could also be used for personalized medicine, testing how a particular patient will respond to different drugs for conditions like heart disease.

Vision loss from fat stem cells

Stem cells can also be found in adults. While embryonic stem cells can turn into any cell in the body, aside from rare newly discovered exceptions, adult stem cells mostly turn into a subset of mature adult cells.

For example, hematopoietic stem cells in blood and bone marrow can turn into any blood cell and are widely used in treating certain cancers and blood disorders.

A major challenge with adult stem cells is getting the right kind of stem cell in useful quantities. This is particularly difficult with eye and nerve cells. Most research is done with accessible stem cell types, like stem cells from fat.

Fat stem cells are also used in stem cell clinics without proper oversight or safety testing. Three patients experienced severe vision loss after having these cells injected into their eyes. There is little evidence that fat stem cells can turn into retinal cells.

Clinical complications

Currently, stem cell based treatments are still mostly experimental, and while some results are encouraging, several clinical trials have failed.

In the brain, despite progress in developing treatment for genetic disorders and spinal cord injury, treatments for stroke have been unsuccessful. Results might depend on method of stem cell delivery, timing of treatment and age and health of the patient. Frustratingly, older and sicker tissues may be more resistant to treatment.

For eye conditions, a treatment using adult stem cells to treat corneal injuries has recently been approved. A treatment for macular degeneration using cells derived from induced pluripotent stem cells is in progress, though it had to be redesigned due to concerns about cancer-causing mutations.

A path of cautious optimism

While scientists have good reason to be interested in stem cells, miracle cures are not right around the corner. There are many questions about how to implement treatments to provide benefit safely.

In some cases, advertised stem cell treatments may not actually use stem cells. Recent research suggests mesenchymal stem cells, which are commonly isolated from fat, are really a mixture of cells. These cells have regenerative properties, but may or may not include actual stem cells. Calling something a stem cell treatment is great marketing, but without regulation patients dont know what theyre getting.

Members of the public (and grad students) are advised to moderate their excitement in favour of cautious optimism.

Katharine Sedivy-Haley, PhD Candidate in Microbiology and Immunology, University of British Columbia

This article is republished from The Conversation under a Creative Commons license. Read the original article.

Original post:
BEYOND LOCAL: Expert recommends 'path of cautious optimism' about the future of stem cell treatment - TimminsToday

Read More...

AVROBIO Announces First Patient Dosed in Phase 1/2 Trial of Gene Therapy for Cystinosis – Business Wire

October 9th, 2019 3:36 pm

CAMBRIDGE, Mass.--(BUSINESS WIRE)--AVROBIO, Inc. (NASDAQ: AVRO) (the Company) today announced that the first patient has been dosed in the Companys AVR-RD-04 investigational gene therapy program for cystinosis, a devastating lysosomal storage disease, in an ongoing Phase 1/2 clinical trial sponsored by academic collaborators at the University of California San Diego. The gene therapy is derived from the patients own hematopoietic stem cells, which are genetically modified to produce functional cystinosin, a crucial protein that patients with cystinosis lack.

The trial will enroll up to six patients with cystinosis, a rare inherited disease caused by a defect in the gene that encodes for cystinosin. The cystinosin protein enables transport of the amino acid cystine out of lysosomes. When it is absent, cystine accumulates and crystalizes, causing progressive damage to the kidneys, liver, muscles, eyes and other organs and tissues. Cystinosis affects both children and adults; they face shortened life spans and often painful symptoms, including muscle wasting, difficulty breathing, blindness and kidney failure.

Cystinosis is a debilitating and progressive disease, and new treatment options are sorely needed. The current standard of care does not avert deterioration; at best, it can attenuate symptoms. Thats why gene therapy is particularly exciting: It has the potential to change the course of disease -- and the lives of patients -- by addressing the underlying cause of cystinosis, said Birgitte Volck, MD, PhD, President of Research and Development at AVROBIO. We believe we can engineer patients own stem cells so they sustainably produce the functional protein that is needed to prevent a toxic buildup of cystine and halt progression of the disease. We are so pleased that this investigational gene therapy is now in the clinic in collaboration with Dr. Stephanie Cherqui at UC San Diego.

The single-arm trial will enroll four adults and a potential follow-on cohort of two adults or adolescents at least 14 years of age who are currently being treated with cysteamine, the standard of care for cystinosis. If started at an early age and taken on a strict dosing schedule, cysteamine can delay kidney failure. However, the treatment regimen is highly burdensome, with side effects that can be severe and unpleasant, and many patients find it difficult to adhere to this treatment regimen. Even if compliance is high, cysteamine therapy cannot prevent kidney failure or avert other complications.

For people with cystinosis, there are no healthy days. They must take dozens of pills a day, around the clock, just to stay alive. It is a relentless disease and we urgently need new treatments, said Nancy J. Stack, President of the Cystinosis Research Foundation, which supported development of the gene therapy with more than $5.4 million in grants to Dr. Cherquis lab at UC San Diego. We believe that we are now an important step closer to the potential cure that our community has been working toward for many years.

The trials primary endpoints are safety and tolerability, assessed for up to two years after treatment, as well as efficacy, as assessed by cystine levels in white blood cells. Secondary endpoints to assess efficacy include changes in cystine levels in the blood, intestinal mucosa and skin and cystine crystal counts in the eye and skin. Efficacy will also be evaluated through clinical tests of kidney function, vision, muscle strength, pulmonary function and neurological and psychometric function, as well as through assessments of participants quality of life after treatment. The trial is funded by grants to UC San Diego from the California Institute for Regenerative Medicine (CIRM) as well as the Cystinosis Research Foundation.

This investigational gene therapy starts with the patients own stem cells, which are genetically modified so that their daughter cells can produce and deliver functional cystinosin to cells throughout the body. With this approach we aim to prevent the abnormal accumulation of cystine that causes so many devastating complications, said Stephanie Cherqui, PhD, an Associate Professor of Pediatrics at UC San Diego School of Medicine, and consultant to AVROBIO. We have been working toward this trial for years and we are grateful for all the support that brought us to this moment.

About AVR-RD-04

AVR-RD-04 is a lentiviral-based gene therapy designed to potentially halt the progression of cystinosis with a single dose of the patients own hematopoietic stem cells. The stem cells are genetically modified so they can produce functional cystinosin with the aim of substantially reducing levels of cystine in cells throughout the patients body. Before the infusion of the cells, patients undergo personalized conditioning with busulfan to enable the cells to permanently engraft. The Phase 1/2 clinical trial is being conducted under the name CTNS-RD-04 by AVROBIOs academic collaborators at the University of California, San Diego.

About Cystinosis

Cystinosis is a rare, inherited lysosomal storage disorder characterized by the accumulation of cystine in all the cells of the body, resulting in serious and potentially fatal damage to multiple organs and tissues and the shortening of patients life spans. The kidneys and eyes are especially vulnerable; more than 90% of untreated patients require a kidney transplant before age 20. An estimated 1 in 170,000 people are diagnosed with cystinosis.

About AVROBIO, Inc.

AVROBIO, Inc. is a leading, Phase 2 gene therapy company focused on the development of its investigational gene therapy, AVR-RD-01, in Fabry disease, as well as additional gene therapy programs in other lysosomal storage disorders including Gaucher disease, cystinosis and Pompe disease. The Companys plato platform includes a proprietary vector system, automated cell manufacturing solution and a personalized conditioning regimen deploying state-of-the-art precision dosing. AVROBIO is headquartered in Cambridge, MA and has offices in Toronto, ON. For additional information, visit http://www.avrobio.com.

Forward-Looking Statements

This press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as aims, anticipates, believes, could, estimates, expects, forecasts, goal, intends, may, plans, possible, potential, seeks, will and variations of these words or similar expressions that are intended to identify forward-looking statements. These forward-looking statements include, without limitation, statements regarding the therapeutic potential of our product candidates, the design, commencement, enrollment and timing of ongoing or planned clinical trials, including the ongoing Phase 1/2 trial of the Companys AVR-RD-04 investigational gene therapy, the anticipated benefits of our gene therapy platform, the expected safety profile of our product candidates, timing and likelihood of success of our current or future product candidates, and the market opportunity for our product candidates. Any such statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Results in preclinical or early stage clinical trials may not be indicative of results from later stage or larger scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements, or the scientific data presented.

Any forward-looking statements in this press release are based on AVROBIOs current expectations, estimates and projections about our industry as well as managements current beliefs and expectations of future events only as of today and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that any one or more of AVROBIOs product candidates will not be successfully developed or commercialized, the risk of cessation or delay of any ongoing or planned clinical trials of AVROBIO or our collaborators, the risk that AVROBIO may not realize the intended benefits of our gene therapy platform, including the features of our plato platform, the risk that our product candidates or procedures in connection with the administration thereof will not have the safety or efficacy profile that we anticipate, the risk that prior results, such as signals of safety, activity or durability of effect, observed from preclinical or clinical trials, will not be replicated or will not continue in ongoing or future studies or trials involving AVROBIOs product candidates, the risk that we will be unable to obtain and maintain regulatory approval for our product candidates, the risk that the size and growth potential of the market for our product candidates will not materialize as expected, risks associated with our dependence on third-party suppliers and manufacturers, risks regarding the accuracy of our estimates of expenses and future revenue, risks relating to our capital requirements and needs for additional financing, and risks relating to our ability to obtain and maintain intellectual property protection for our product candidates. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause AVROBIOs actual results to differ materially and adversely from those contained in the forward-looking statements, see the section entitled Risk Factors in AVROBIOs most recent Quarterly Report on Form 10-Q, as well as discussions of potential risks, uncertainties and other important factors in AVROBIOs subsequent filings with the Securities and Exchange Commission. AVROBIO explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.

Read the original:
AVROBIO Announces First Patient Dosed in Phase 1/2 Trial of Gene Therapy for Cystinosis - Business Wire

Read More...

A Doctor Plumbs The Depths Of Ivan Doig’s Illness And Asks: ‘Did He Have An Epiphany?’ – Mountain Journal

October 9th, 2019 3:36 pm

I grew up in Ohio and met my first real Westerner at age 27. Kate was from Durango, Colorado and lived next door to me for two months during a rural primary care rotation in medical school. They rolled up the sidewalks at night in Twin Falls, Idaho and so we had plenty of time to talk. Books always figured prominently in the conversation and she recommended her favorite book about the West

Reading that first iconic chapter, Time Spent, led to a 25-year Doig odyssey that eventually landed me in a Montana State University archive reading the final draft of that same chapter, marked up with Ivans own red pen.

It begins, That start of memorys gather: June 27, 1945. I have become 6 years old, my mothers life has drained out at 31 years. And in the first grey daylight, dully heading our horses around from that cabin of the past, my father and I rein away toward all that would come next.

The Doig archive at Montana State is a treasure trove for fans. Its extensively indexed and entirely on line and filled with pictures, original manuscripts and the collection of 3 x 5 and 5 x 8 cards on which Doig kept quotes and observations from his extensive research travels in Montana.

Ivan kept box after box of these cards, many of them with only a single type written sentence, sometimes annotated in longhand. He shuffled and reshuffled these bits of memory assembling them into temporary collections as material to flesh out a particular character or story line and then returned them to their boxes only to be reshuffled and reassembled for the next novel.

In summer 2019, Carol Doig met with a group of visitors and discussed her husband's journey in his last years. Joining them was her close friend, Betty Mayfield, who helped assemble Doig's edited manuscripts, diaries, correspondence and other documents that today are part of the MSU Doig collection. Those joining Carol in her living are, left to right, Betty Mayfield, Dr. Rob Patrick, Justin Shanks a post-doctoral fellow working on the Doig material to make it digitally accessible, and writer Todd Wilkinson of Mountain Journal. Photo by Kenning Arlitsch, dean of MSU Libraries

Sometimes this shuffling was frozen into a more permanent form when he collected them into 2-to-3 page novellas with titles like Scotchisms and Curses.Most assumptions arent conscious until they are shattered. Without realizing it, I had cast my favorite writer in his own movie that ran only in my head.

He woke up in the morning, hunted big game, slept with the world's most beautiful women, cavorted at the Algonquin round table, drank his weight in scotch and then, late at night, great work flowed forth from his pen in a tortured and inspired torrent. He threw himself down exhausted, only to arise and repeat the performance with the dawn. The truth that emerged from touching the physical remnants of his process was far different.

Ivan Doig was . . . a nerd . . .just like me. I clipped articles and collected them in folders, wrote down random thoughts and observations on cards, restacked, hoarded and recombined information. My stories were just about thrombocytopenia and clonal proliferation instead of resilient ranchers scraping out an existence under the Big Sky.

The champion of the lariat proletariat was a closet geek. How disappointing.But my biggest disappointment was yet to come.The archive contained an odd and alluring folder title medical journey that was irresistible to me as a physician. I hadnt realized that Ivan suffered from multiple myeloma for the last eight years of his life and had written four books after being diagnosed with a terminal disease.

Myeloma is a strange form of cancer as cancers go, it is both painstakingly slow to progress and inexorably fatal. Patients rack up complications from the treatment, not because treatment is so toxic, but because they live long enough to suffer from the cure as well as the disease.

The core of the pathology is something called a plasma cell which under normal circumstances produces the antibodies that help fight off invading viruses and bacteria. In myeloma, a single plasma cell mutates and grows uncontrollably crowding out everything else in a patients bone marrow and gumming up their organs with immunoglobulin. The mutant cells eventually cant be contained inside the bone marrow and invade the surrounding solid bone causing painful fractures in the spine and long bones of the skeleton.

As if that was not bad enough, the core of chemotherapy is high dose steroids, usually dexamethasone or prednisone. Steroids are the poster child for double edged swords in medicine. They are simultaneously incredibly useful for suppressing the immune system in autoimmune diseases, cancer and anything that involves inflammation, while at the same time having the most broad ranging side effect profile of almost any medication.

It was a love for wildlands in the West that led Rob Patrick, at right, down the trail of Ivan Doig's books and when he had an opportunity to dive deeper into Doig's final years he jumped at the chance. Another thing that brought him to Bozeman and Greater Yellowstone is his close friendship with Kenning Arlitsch, Dean of MSU Libraries. Here they are on an autumn trip into the Yellowstone backcountry.

Probably the most serious side effects for myeloma patients are immunosuppression leading to increased risk for infection, a softening of the bones accelerating the tendency of the disease to cause fractures and emotional lability. The last of these sounds trivial, but isnt.

My first patient who suffered from this particular side effect literally started a sentence laughing and ended it crying. The cognitive effects can be especially debilitating, because at its peak, the drug lulls one into a false sense of security. It can make patients feel super human and I had one multiple sclerosis patient tell me it was the most powerful antidepressant she had ever taken and she almost looked forward to her next flare so she could get it again. However, on the way up and the way down it can cause confusion and a loss of emotional control that is profoundly disturbing, especially to someone who depends on their brain to make a living. Truly a blessing and a curse of modern medicine.

One of my biggest losses of innocence after medical school was realizing that professors had pulled the wool over my eyes concerning one of the fundamental diagnostic tools in medicinethe patient history. During the pre-clinical years you seldom get to talk to an actual patient and instead hone your skills using case presentations which I later came to understand were carefully curated stories masquerading as actual patients in which the non-salient details were conveniently expunged and the salient ones amplified for teaching purposes.

My teachers smugly told me, If you dont know whats wrong by the time you finish taking the history, take the history again." This illusion is perpetuated during third year clerkships when cases are cherry picked for medical students so as not to dispel the myth. The gloves come off during internship when it is too late to turn back and you realize that most patients have a hard time telling you how they feel no matter how many creative ways you come up with to ask the same question. Its not their fault, they usually just have never felt like this before and dont have the words to describe it.

When you add intoxication, mental illness, dementia, etc. to the mix, taking a history often becomes an exercise in communication breakdown and frustration. So imagine my joy at finding a history written by a professional communicator whose livelihood depended on his ability to observe the world and record it. It was like winning the internal medicine lottery.

Doig observed of myeloma: The waiting room of hell, furnished with side effects.

Of those side effects, he observed, The dex makes me longitudinal - - concentrated on a single line of endeavor at a time, no latitude to speak of and I would go to blow my nose and find there was not a handkerchief within 50 of me. Pill bottle caps leapt for the floor. My ordinary thought process resembles a homesteader digging out a stump, when loaded with dex I plodded right past nuances of life in temporary fixations on getting to my desk and writing things down. Which, amazingly, produced pages of a novel faster than when I wasnt taking the stuff. Dex gave me a mental pop, off-the-chart energy upstairs while it played games with the rest of me. Writing proved to be therapy for therapy.

On the topic of mortality, he explained in a written passage, I am now in remission, that terra incognita but better than being off the map(oblivion). He would add, I have not come out of this as any cheerleader for Nietzche: thera are countless preferable ways to strengthen in life without having something trying to kill you.

Facing the reality, he noted, Invariably fatal. Damn. But then, so is life. Its probably not polite to laugh out loud at the writings of a dying man, but I couldnt help myself and I also couldnt help wondering what a pleasure it would have been to take care of him. There was plenty of correspondence in the archive between Ivan and his doctors, but the most striking examples would probably have been overlooked by the uninitiated. The age of electronic medical records and e-mail allow patients unprecedented access to providers.

Like most technology, this chart messaging is both a blessing and a curse. The blessing is that it doesnt take three phone calls to catch a patient at home and tell them about their lab results.

The curse is the dozens of chart messages to return at the end of a busy day. Consequently, as Doig chronicled, brevity is the rule: Everything normal on your labs today, see you in 6 months."

Doig, when in his prime, trying to instill the lessons of history into his work. Here he absorbs the vibe in an abandoned farm house where heart-felt dreams rose, fell part like a heartache and drifted away. Photo by Carol Doig, courtesy MSU Library Doig Archives

The messages from Ivans providers went on for paragraphs, like post cards from your grandmother, and often came close to open displays of affection. All patients are equal, but some are more equal than others.

My day in the Doig archive was followed by an evening at the annual trout lecture hosted by the MSU library and I happened to find the only other Doig nerd who had spent any time with the medical journey files. Todd Wilkinson, the editor of Mountain Journal, shared my fascination with this little known part of Ivan Doigs life and suggested we pursue an event centered around his medical journey.

I couldnt imagine who else would show up to hear about such a niche topic, but didnt want to spoil the glow of our mutual fandom and encouraged him to pursue it. Three months later I found myself sitting in Carol Doigs living room in Seattle.This would be a good time to disclose that I am not a casual Doig fan. Im not a religious person, but I have made two literary pilgrimages in my life. The first was to Arches National Park to find the location of Edward Abbeys trailer from Desert Solitaire and the second was to White Sulfur Springs, Montana to see the place that had figured so prominently in Doig'sThis House of Sky.

Something still haunted me about the archives. Aside from the few pithy quotes above, there wasnt much mention of how Ivan faced his own mortality. How does an author get up every day and write four more novels when he knows hes dying? More importantly, why does he do it?

My practice over the last 20 years was working as a hospitalist. All of my patients were sick enough to be in the hospital and these days you have to be pretty sick to make it through those doors. I had seen hundreds of patients die and typically had end of life conversations with patients and families several times a week. Indeed, I had been on a personal crusade in the last few years to get doctors to talk with their terminally ill patients about their goals for the end of life and had coached other providers about how to do it.

So here was my chance to salvage something of my shattered romantic ideal about writers. Ivan must have had some big epiphany, I thought, that just wasnt there in his writing and my task was to extract it from his widow. I was as if a literary anthropologist on a mission.

It led to having a wonderful day in Seattle, sunny and warm; the Doig living room had a commanding view of Puget Sound. The house was spare and elegant and warm and inviting all at the same time and I got to see Ivans personal desk with his typewriter and his book collection.

Carol was charming and intelligent and well educated and everything you would expect from the spouse of your literary hero. Todd Wilkinson was there and Kenning Arlitsch, Dean of Libraries at MSU, too, and the person responsible for securing the Doig archive. Our conversation flowed easily.

Todd had a flurry of journalistic questions for Carol about Ivan and his writing. I was the final interviewer and my experience told me that it was almost always the wife that was the keeper of the medical history. So I started with some easy logistical questions.

Doig's desk, where he completed five books in eight years, battling through pain, the effects of medicines and a bone marrow transplant. All this and yet critics say these final works contain passages that are among the most incisive and moving of his four-decade long career. Photo by Todd Wilkinson

No, she did not go to all of his medical appointments with him and she didnt even know about the folder where he had kept all of the materials about his illness until after his death. There goes my first assumption.

We walked through the chronology of his illness, his initial diagnosis, the stem cell transplant, chemotherapy, remission, relapse, second line chemotherapy. What was daily life like? How did they deal with telling friends and family since he was not obviously ill until the end? How long was he on hospice? What was it like at the end? I probed, I rephrased, I asked the same question a different way. But there was no profound epiphany.

What she described instead was a guy who got up every day, made breakfast, went to his study and pounded out his words for the day. If he finished a novel on Friday, he started the next on Monday. A literary proletarian if there ever was one.

I have watched plenty of people die in my career, some face it with grace and dignity and resolve and some fight it and raise their fist against the sky until the last breath. What separated those who faced their end well from those who didnt?

Regret. Regret for things they hadnt done or relationships that had soured, but it boiled down to not living life the way they wanted to. My epiphany was that there was no epiphany. Epiphanies are extraneous when you are already living your best life. Ivan Doig was a wonderful writer, husband, friend, and colleague. If it isnt broken, dont fix it.

Read more:
A Doctor Plumbs The Depths Of Ivan Doig's Illness And Asks: 'Did He Have An Epiphany?' - Mountain Journal

Read More...

‘The View’: Priyanka Chopra recalls checking on Nick Jonas ‘in the middle of the night’ – USA TODAY

October 9th, 2019 3:35 pm

Power couple Priyanka Chopra and Nick Jonas walk the red carpet for Chopard party, along with Amber Heard, Elle Fanning, Julianne Moore and Richard Madden (May 18). AP, AP

Priyanka Chopra is opening up about what life is like with husband Nick Jonas, who is a type 1 diabetic.

The 37-year old actress described how much she admires Jonas' dedication to his healthon "The View"Tuesday.

Initially, when we first got married, I couldnt wrap my brain around the fact that he knew when his sugar dropped, even whilehe was sleeping, shesaid. He feels it.

Though she trusts Jonas' "crazy discipline" about monitoring his blood sugar, Chopra confessed she "used to wake up in the middle of the night" to make sure her husband was OK.

She also praised Jonas, 27, for not letting his disorder affect the way he lives.

"He lives the biggest life possible," she said."He's not restricted himself from anything. He plays sports. He's touring. He lives an incredible life, and it's so inspiring to see."

This passion for living life to the fullest, Chopra said, is what inspired Jonas to found Beyond Type 1, a nonprofit organization dedicated to diabetes education, advocacy and the path to a cure.

More: Priyanka Chopra explains why she took Nick Jonas' name: I'm 'old-school like that'

More: Priyanka Chopra spars with upset fan at BeautyCon: 'Girl, don't yell'

"That's what he wanted to show people," Chopra said. "That even if you have type 1 diabetes doesn't mean that your life has to be different. You can live it to its fullest, and it's so inspiring to me."

According to Mayo Clinic, type 1 diabetes is a chronic condition in which the pancreas produces little or no insulin. Though there is no cure, treatment "focuses onmanaging blood sugar levels with insulin, diet and lifestyle to prevent complications."

More: Awww! Nick Jonas writes fairy-tale 'one year' love letter to wife Priyanka Chopra

See our full coverage of entertainment news

Autoplay

Show Thumbnails

Show Captions

Read or Share this story: https://www.usatoday.com/story/entertainment/celebrities/2019/10/08/nick-jonas-lives-biggest-life-despite-diabetes-priyanka-chopra-says/3914879002/

See more here:
'The View': Priyanka Chopra recalls checking on Nick Jonas 'in the middle of the night' - USA TODAY

Read More...

Drinking more soda and juice tied to increased diabetes risk – Reuters

October 9th, 2019 3:35 pm

(Reuters Health) - People who increase their consumption of sodas, juices and other sweet drinks over time are more likely than those who dont to develop diabetes, a U.S. study suggests.

Researchers examined over two decades of data from more than 192,000 men and women who worked in nursing or other healthcare jobs. None of the participants had diabetes at the start of the study; by the end almost 12,000 people had developed the disease.

After accounting for how much people weighed and their overall eating patterns, researchers found that those who increased their total consumption of sugary drinks by a half serving a day over four years were 16% more likely to develop diabetes over the next four-year period. With the same daily half-serving increase in artificially-sweetened drinks, the odds went up 18%.

Even though consumption of 100% fruit juices has been considered a healthy alternative to sugar-sweetened beverages because of the vitamins and minerals in fruit juices, they typically contain similar amounts of sugar and calories as sugar-sweetened beverages, said Jean-Philippe Drouin-Chartier, lead author of the study and a nutrition researcher at the Harvard T.H. Chan School of Public Health in Boston.

The study results raise concerns about the negative health effects of sugary beverages, regardless of whether the sugar is added or naturally occurring, Drouin-Chartier said by email.

The researchers focused on type 2 diabetes in the study, the most common form of the disease, which is associated with obesity and aging.

They also found that when people replaced sodas, juices and other sugary beverages with other kinds of drinks, their risk of developing diabetes went down.

Replacing one serving a day of sugary drinks with water, coffee or tea, was associated with a 2% to 10% lowering of diabetes risk. The data did not include information about whether people added sugar to their coffee or tea, the study team notes.

The analysis also wasnt designed to prove whether or how drink selections might directly impact the development of diabetes.

Its possible that diet sodas and other artificially-sweetened drinks were tied to higher diabetes risk because people switched to these beverages after they developed diabetes or realized they were on track to get the disease, the study team acknowledges in Diabetes Care.

However, the results should still serve as a reminder that even some sugary drinks that people think of as healthy - like orange juice - can still lead to elevated blood sugar and contribute to the development of diabetes, said Dr. Robert Cohen, a diabetes researcher at the University of Cincinnati College of Medicine in Ohio, who wasnt involved in the study.

Sugary beverages that people might otherwise think of as being healthy provide a load of sugar (sucrose) which gets broken down to glucose and raises blood glucose, Cohen said by email. Removing or markedly reducing beverages like fruit juices can have a dramatic effect to improve blood sugar control.

SOURCE: bit.ly/321TZI0 Diabetes Care, online October 3, 2019.

Excerpt from:
Drinking more soda and juice tied to increased diabetes risk - Reuters

Read More...

‘None of Them Survived’: Diabetes in the Time of Humanitarian Crises – Medscape

October 9th, 2019 3:35 pm

This transcript has been edited for clarity.

I first became passionate about diabetes and humanitarian crises when I spent a month practicing general internal medicine at a small district hospital near the Congo-Rwanda border. We had many refugees come through from the Congo at that time, including a number of young men who were clearly in diabetic ketoacidosis.

Because we did not have insulin or glucose strips with which to monitor them, they all died within hours of presenting to the hospital. None of them survived. Those with type 2 diabetes kept being readmitted to the hospital because we were unable to manage their hyperglycemia, although we were able to manage their infections or trauma.

This experience led me to dedicate my career to this issue. Today, about half a billion people worldwide are affected by diabetes, 80% of whom are living in low- and middle-income countries. This is projected to increase over the next 20 years as a result of urbanization, climate change, global warming, etc., so the crisis will get even worse.

At the same time, low- and middle-income countries are predominantly and disproportionately affected by humanitarian crises. Most people who are displaced due to conflict spend decades as refugees or internally displaced people. The average duration of this conflict-induced displacement is 27 years, and these people have diabetes. As a result, humanitarian actors are now having to take on broader roles.

Yet, at present, data on this issue are not being collected. There are no evidence-based guidelines on how to manage diabetes best in these circumstances, and there is no education. Medicines, including insulin, are not routinely supplied in these contexts, which is a death sentence for anyone with type 1 diabetes.

For this reason, we organized a symposium in early April at Harvard University, where we convened more than 100 leaders in global and humanitarian health, including various academic institutions, the Centers for Disease Control and Prevention, the World Health Organization, and pharmaceutical and diagnostics companies. The objectives were to discuss this issue, build partnerships, figure out how to collaborate, prioritize the most immediate needs as a community, and design projects going forward.

Out of that meeting, we published the Boston Declaration in TheLancet Diabetes & Endocrinology, which outlines this incredible and urgent need for insulin, especially for those with type 1 diabetes, and the need for chronic care for people with type 2 diabetes.[1] This care includes cardiovascular risk management and all comorbidities, which would hopefully pave the way for improved care for other chronic diseases.

The group, comprising 64 signatories from about 43 different organizations, outlined four major targets to work toward. The first is improved advocacy and global awareness, which is a major need. The second is improved access to insulin, essential medicines, and diagnostics for diabetes and hypertension. The third major target is to develop improved clinical and operational guidelines that are coherent among organizations, and the last target is improved data collection, surveillance, and monitoring across organizations. These are the four main targets that we're setting out to tackle over the next 3 years.

Many new projects are beginning, and we would love everyone's involvement. If you would like to get involved, you can contact me via the Global Endocrinology website, or contact any humanitarian organization, including Doctors Without Borders, the International Committee of the Red Cross, and Save the Children. They're all doing phenomenal work, they definitely need this money, and they will put it to good use.

Thank you.

Follow Medscape on Facebook, Twitter, Instagram, and YouTube

Read more:
'None of Them Survived': Diabetes in the Time of Humanitarian Crises - Medscape

Read More...

The Number of Adults with Diabetes Worldwide is Set to Rise Nearly 50% to Approximately 629 Million by 2045 – Yahoo Finance

October 9th, 2019 3:35 pm

DUBLIN, Oct. 9, 2019 /PRNewswire/ -- The "Diabetes Management: Insulin Pumps Market (2019)" report has been added to ResearchAndMarkets.com's offering.

Research and Markets Logo

Valued at nearly $3bn in 2018, the Global Insulin Pumps Market is growing at a fast pace - at a compound annual growth rate (CAGR) of approximately 12% - reaching more than $5bn by 2023

The Global Insulin Pumps market is being driven by strong demand, increasing awareness and adoption of next-generation hybrid closed-loop systems, solid clinical outcomes, and good reimbursement. Market penetration is low, leaving much room for growth.

According to the International Diabetes Federation (IDF), approximately 425 million adults (20-79 years of age) have diabetes worldwide, and this number is expected to rise nearly 50% to approximately 629 million by 2045. More than 1.25 million people have type 1 diabetes in the US alone.

There is a strong need for automated continuous insulin delivery as a replacement for cumbersome multiple daily (insulin) injections (MDI) using painful pens/needles, which are prone to user error and may leave many type 1 (and insulin-requiring type 2) patients at risk for dangerous complications.

Overall, the insulin pumps market is an evolving market driven by innovation. While Medtronic clearly dominates, technological advances are spurring intense competition. There is a rush to develop even smarter automated hybrid closed-loop systems (artificial pancreas or AP systems) driven by machine learning or artificial-intelligence-based algorithms. These systems lessen patient burden and autonomously adapt to individuals' glycemic needs and lifestyles to significantly improve blood glucose control and quality of life for millions of diabetes patients worldwide.

This comprehensive medical market and technology report provides:

Markets covered by this analysis include the US, Japan, the five major EU markets (France, Germany, Italy, Spain, and the UK), and the Rest of World (RoW) markets, which includes all other countries. Market forecasts are for the 2018-23 time period.

Highlights

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/ghc0vu

About ResearchAndMarkets.comResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/the-number-of-adults-with-diabetes-worldwide-is-set-to-rise-nearly-50-to-approximately-629-million-by-2045-300934663.html

Visit link:
The Number of Adults with Diabetes Worldwide is Set to Rise Nearly 50% to Approximately 629 Million by 2045 - Yahoo Finance

Read More...

Type 2 diabetes: Eat this fruit three times a day to lower your blood sugar levels – Express

October 9th, 2019 3:35 pm

Type 2 diabetes means a persons pancreas cannot produce enough insulin to regulate blood sugar levels. Overtime, unchecked blood sugar levels pose serious health risks, such as heart disease. Fortunately, certain dietary decisions can help to control blood sugar levels. Evidence singles out a particular fruit.

According to research presented at the American Diabetes Association's 72nd Annual Scientific Session, eating raisins three times per day may reduce post-meal sugar spikes significantly.

The research, conducted by Harold Bays, MD, medical director and president of Louisville Metabolic and Atherosclerosis Center (L-MARC), involved 46 adults who had slight increases in glucose levels, but no previous diagnosis of diabetes mellitus.

The researchers randomly assigned participants to two groups.

The first group was told to snack on raisins three times per day for 12 weeks, while the second group snacked on pre-packaged snacks that did not contain raisins or other fruits or vegetables.

The researchers found that raisins slashed post-meal glucose levels by 16 per cent and reduced mean hemoglobin A1c by 0.12 per cent from baseline.

Pre-packaged commercial snacks on the other hand, did not significantly reduce mean post-meal glucose or hemoglobin A1c.

As Diabetes UK explained, HbA1c is a persons average blood glucose (sugar) levels for the last two to three months. A high HbA1c means a person has too much sugar in their blood.

Commenting on the findings, Dr. Bays said: "Compared to the snacking control group, the group consuming raisins had a significant statistical reduction in their after-liquid meal blood sugar levels among study participants who had mean baseline fasting glucose levels between 90 and 100 mg/dl.

Adding: This favourable glucose effect of raisins was further supported by the statistically significant reduction in hemoglobin A1c (a standard test for overall blood sugar control in diabetes mellitus) in the within group comparison to baseline. The within group comparisons from baseline with snacks did not demonstrate a reduction in hemoglobin A1c."

Accounting for the results, James Painter, Ph.D., R.D., and nutrition research advisor for the California Raisin Marketing Board, said: "Raisins have a relatively low glycemic index and contain fiber and antioxidants, all factors which contribute to blood sugar control. Decreasing blood sugar and maintaining normal hemoglobin A1c levels is important because it can prevent long-term damage to the heart and circulatory system."

Why eat fruit?

As Diabetes UK explained, there is a popular misconception that the sugar content of fruit means it is off-limits for people with type 2 diabetes. But the sugar in whole fruit does not count towards free sugars, so it is not this type of sugar we need to cut down on, said the health body.

Adding: This is different to the free sugar in drinks, chocolate, cakes and biscuits.

In fact, carbohydrate intake has the biggest impact on blood sugar levels, and fruit is a low-carb alternative to sugary foods, noted the health site.

It said: A portion of fruit, such as a medium apple, generally contains about 15 to 20g carbs, a chocolate muffin has 55g carbs and a 500ml ordinary fizzy drink has 54g carbs.

Here is another superfood proven to lower blood sugar levels.

What are the symptoms of type 2 diabetes?

Symptoms of type 2 diabetes include:

Read more:
Type 2 diabetes: Eat this fruit three times a day to lower your blood sugar levels - Express

Read More...

Page 859«..1020..858859860861..870880..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick